Evaluation of the validity of pancreatoduodenectomy in older patients with distal cholangiocarcinoma in terms of recurrence

Evaluation of the validity of pancreatoduodenectomy in older patients with distal cholangiocarcinoma in terms of recurrence | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Evaluation of the validity of pancreatoduodenectomy in older patients with distal cholangiocarcinoma in terms of recurrence Wataru Izumo, Hiromichi Kawaida, Ryo Saito, Yuki Nakata, Hidetake Amemiya, and 10 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4688865/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 03 Apr, 2025 Read the published version in Langenbeck's Archives of Surgery → Version 1 posted 10 You are reading this latest preprint version Abstract Background This retrospective study investigated the validity of pancreatoduodenectomy (PD) with regard to recurrence in older patients with distal cholangiocarcinoma (DC). Methods We compared 32 patients aged ≥ 75 years and 68 patients aged < 75 years who underwent PD for DC, and evaluated the relationship between age, clinicopathological factors, and outcomes. Results Postoperative mortality and morbidity rates did not differ between the groups. Although there were no significant differences in 5-year recurrence, disease-specific survival, and overall survival rates between the groups (44.5, 61.5, and 55.0% in patients ≥ 75 years and 48.7%, 63.0%, and 58.5% in patients < 75 years; P = 0.82, 0.57, and 0.34, respectively), the median time from recurrence to death (RTD) in older patients was significantly shorter than that in younger patients (0.6 years vs 1.3 years, P = 0.020). In multivariate analysis, age ≥ 75 years (hazard ratio [HR]: 3.5), controlling nutritional status (CONUT) score ≥ 4 (HR: 4.7), poorly-differentiated adenocarcinoma or adenosquamous carcinoma (HR: 4.7), and failure to implement treatment after recurrence (HR: 5.8) were independent risk factors for a short time from RTD. Furthermore, at the time of recurrence, older patients had significantly poorer serum albumin levels, prognostic nutrition index, Glasgow prognostic score, and CONUT score. Age ≥ 75 years (odds ratio: 0.24) was an independent risk factor for implementation of treatment after recurrence. Conclusions PD in older patients may be acceptable; however, the median time from RTD was shorter owing to lower nutritional status and rates of treatment implementation after recurrence. elderly pancreatoduodenectomy distal cholangiocarcinoma prognosis recurrence Figures Figure 1 Figure 2 Introduction Although the incidence of biliary tract carcinoma (BTC) is higher in parts of Asia and South America, its incidence has been increasing in Europe and the United States. 1 – 3 Based on the anatomical site of origin, BTC is classified into intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, gallbladder carcinoma, distal cholangiocarcinoma (DC), and ampullary carcinoma, and each type is thought to have different biological characteristics and malignancy grades. 3 Radical surgical resection is the only curative treatment option for patients with BTC regardless of the anatomical site of origin and pancreatoduodenectomy (PD) with regional lymph node dissection (LND) is the standard operative procedure for DC. 4 – 6 In recent years, advances in surgical techniques and pre- and postoperative management have improved the safety of PD, 7 , 8 and the number of patients undergoing PD has been rising in Japan. 8 However, PD remains one of the operative procedures with the highest risk of complications and surgery-related mortality rates among all gastrointestinal surgeries; 8 therefore, the indications for PD should be carefully considered. Recent advances in medical technology have extended the life expectancy worldwide, 9 and the number of older people requiring medical interventions is increasing. The decision regarding whether to provide aggressive medical treatment to older people is complex and involves a variety of factors, including social, economic, and ethical considerations. Furthermore, there is no universal definition of older people or the “elderly.” Japan is one of the countries with the longest life expectancy. 10 People aged 75 years or older are considered "Late-stage elderly" and are covered by a medical insurance system which is different from that covering people aged under 75 years. 11 However, this is merely a systemic categorization and does not convey the essential meaning of "elderly." However, surgery in older patients is associated with certain risks because of decrease in tissue fragility, muscle strength, cardiopulmonary function, and physiological reserve capacity with age. 12 , 13 Therefore, while it is considered unacceptable to withhold treatment solely because of age, it is an important factor influencing treatment selection. In addition, although immune inflammatory markers and nutritional indices have been reported to affect the prognosis of patients with various gastroenterological diseases, 14 – 16 their role as prognostic predictors in older people remains unclear. Some studies have reported that the safety and effectiveness of PD in older patients are equivalent to those in younger patients, 17 – 20 while other studies have claimed that they are inferior, 21 – 24 and no definite conclusion has been reached yet. In particular, PD is used for the surgical treatment of carcinoma of the pancreatic head as well as DC. Nevertheless, the prevalence of BTC in patients aged 75 years or older is reportedly higher than that of pancreatic cancer (67.9% vs 55.4%). 25 The oncological significance of PD in older patients with DC remains unclear. Furthermore, postoperative treatment and treatment after recurrence are predicted to be difficult in older patients with DC; however, to our knowledge, no studies have compared these factors between older and younger patients with DC. This study aimed to clarify the surgical and oncological validity of PD in older patients with DC, with a focus on recurrence. Large-scale observational studies are required to confirm the findings of this preliminary pilot study. Methods Study design This study was approved by the institutional review board of Yamanashi University (approval number: H30906). The requirement for informed consent was waived owing to the retrospective nature of the study. Between 2000 and 2023, 143 patients underwent surgical resection of DC at the Department of Digestive Surgery, University of Yamanashi Hospital. We excluded patients who underwent hepatopancreatoduodenectomy (HPD), extrahepatic bile duct resection and reconstruction, residual tumor (R2) resection, and those with an unknown examination status. Finally, 100 patients who underwent curative PD for DC were analyzed retrospectively. We evaluated the following clinicopathological parameters and their association with recurrence, time from recurrence to death (RTD), and outcomes. Preoperative parameters included age, sex, body mass index, serum levels of total protein, albumin, total cholesterol, triglyceride, C-reactive protein, hemoglobin A1c, neutrophil-to lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), prognostic nutrition index (PNI), C-reactive protein/albumin ratio, Glasgow prognostic score (GPS), controlling nutritional status (CONUT) score, carcinoembryonic antigen, carbohydrate antigen 19 − 9 (CA19-9), and American society of anesthesiologists-physical status. 26 Intraoperative parameters comprised vascular resection, number of LND, duration of surgery, and amount of blood loss, while postoperative parameters included pathological type, local invasion, vascular invasion, lymph node metastasis (LNM), existence of residual tumor, postoperative complication grade, postoperative pancreatic fistula (POPF), delayed gastric emptying (DGE), post- pancreatectomy hemorrhage (PPH), completion of adjuvant chemotherapy, length of postoperative hospital stay, hospital mortality, recurrence, implementation of treatment after recurrence, cause of death, and prognosis. Multivariate analyses of recurrence-free survival (RFS), RTD, disease-specific survival (DSS), and overall survival (OS) were performed by incorporating the above factors. Surgical procedure PD was performed if the patient expressed a wish to undergo PD and if it was medically indicated, after considering the patient’s comorbid status. In patients who underwent PD, the LND region included the area in the hepatoduodenal ligament, area around the common hepatic artery, celiac artery, and superior mesenteric artery, as well as the anterior and posterior surface of the pancreatic head. Portal vein and superior mesenteric vein resections were performed in patients with confirmed or suspected invasion or infiltration of these vessels. The decision regarding the extent of LND and vascular resection was ultimately made at the discretion of the surgeon, while taking into account the patient’s condition and age. Definitions Preoperative laboratory and imaging data were acquired within 1 month of surgery, while laboratory data were measured after biliary decompression with the total bilirubin level < 3.0 mg/dL. The final stage of DC was pathologically defined using the eighth edition of the Union for International Cancer Control criteria. 27 Postoperative complications were rated according to the Clavien-Dindo classification, 28 while POPF, DGE, and PPH were defined according to the International Study Group of Pancreatic Surgery. 29 – 31 The cut-off values for the above factors were determined using receiver operating characteristic (ROC) analysis and designated as the point at which the area under the ROC curve was the largest. Adjuvant chemotherapy Adjuvant chemotherapy was administered for 6 months as a standard practice in patients with stage ≥ I whose general post-surgical condition was stable. Ultimately, the decision to give adjuvant chemotherapy was based on the physician’s and patient’s choice. Adjuvant chemotherapy was previously performed with a variety of regimens at our institute; however, in this study, adjuvant chemotherapy was defined as treatment with capecitabine or S-1 after 2019, when evidence was established. 32 , 33 In this study, adjuvant chemotherapy was defined to include only patients who were initiated within 10 weeks after surgery and received more than 80% of the planned dose. Follow-up All patients underwent laboratory examinations, including for tumor markers every 1–3 months for the first 3 years and every 3–6 months after 3–5 years postoperatively, whereas imaging studies were performed every 3 months for the first 3 years and every 3–6 months for 3–5 years postoperatively. RFS was calculated from the time of surgery until recurrence, whereas RTD was calculated from the time of recurrence until death or the last follow-up date. Short RTD was defined as death within six months of recurrence. OS was calculated from the time of surgery until death or the last follow-up date. Recurrence Recurrence was defined as the presence of a tumor on postoperative imaging studies. When two or more sites of recurrence were observed simultaneously, all of the sites were counted. An increase in the tumor marker levels only was not defined as a recurrence in this study. Local recurrence was defined as locoregional recurrence, including that in the nerve plexus. Lymph node recurrence was defined as an increase in the number of nodes on imaging studies. Liver or lung recurrence was defined as a liver or lung mass detected on imaging studies. Peritoneal dissemination recurrence was defined as the detection of an abdominal mass with ascites or peritoneal thickening. Treatment after recurrence The first treatment administered after recurrence was designated as the treatment after recurrence. In this study, only surgical resection, radiation, or drug therapy were included in treatment after recurrence. Drug therapy included only gemcitabine alone, S-1 alone, gemcitabine plus S-1, gemcitabine plus cisplatin (GC), GC plus S-1 (GCS), or GC plus durvalumab (GCD). 34 , 35 Treatment administered to alleviate symptoms alone was not included in treatment after recurrence. Implementation of treatment after recurrence was defined as at least one treatment after recurrence. Ultimately, the decision to undergo treatment after recurrence was based on the physician’s and patient’s choice. Statistical analysis Univariate and multivariate analyses were performed to determine the independent predictors of RTD, DSS, and OS. Survival analyses were performed using the Kaplan-Meier method, log-rank test, and Cox proportional hazards model. Only the factors that were significant in the univariate analysis were subjected to multivariate analysis. Statistical significance was set at P < 0.05. All analyses were performed using JMP 17.0.0 for Windows (SAS Institute Inc., Cary, NC, USA). Results The preoperative patient characteristics are shown in Table 1. In this study, 32% of the patients were aged ≥ 75 years and 68% were aged < 75 years. There were no significant differences in the pre-, intra-, and postoperative factors other than age, including the levels of various immune-inflammatory markers, nutritional index, frequency of postoperative complications, mortality rates, duration of postoperative hospital stay, and completion of adjuvant chemotherapy between the two groups. Recurrence rate, RFS, DSS, and OS The recurrence rate was 52% (52/100) in all patients; 50% (16/32) in patients aged ≥ 75 years and 53% (36/68) in patients aged < 75 years, with no significant difference between the two groups (P = 0.78). The recurrence sites (with duplication) were mainly the liver (20 patients, 38%), followed by the lymph nodes (17 patients, 33%), local recurrence (13 patients, 25%), lungs (eight patients, 15%), and dissemination (seven patients, 13%). There were no significant differences in the 5-year RFS, DSS, and OS between the two groups (44.5, 61.5, and 55.0% in patients ≥ 75 years; 48.7%, 63.0%, and 58.5% in patients < 75 years; P = 0.81, 0.57, and 0.34, respectively) (Figure 1). Poor prognostic factors in resected patients In multivariate analyses, a preoperative CONUT score ≥ 4, poorly-differentiated adenocarcinoma or adenosquamous carcinoma, existence of LNM, and residual tumor (R1 resection) were poor prognostic factors for OS (hazard ratio [HR]: 4.9, 2.8, 3.6, and 2.4, respectively), while age ≥ 75 years was not a significant adverse prognostic factor (Table 2). Similarly, a preoperative CONUT score ≥ 4, CA19-9 ≥ 95.7 U/mL, poorly-differentiated adenocarcinoma or adenosquamous carcinoma, and existence of LNM were poor prognostic factors for DSS (HR: 3.0, 2.8, 2.4, and 2.2, respectively), while age ≥ 75 years was not a significant adverse prognostic factor (Supplemental Table 1). Recurrence status and risk factors for short RTD The patient characteristics at the time of recurrence are shown in Table 3. At the time of recurrence, serum albumin level, LMR, and PNI were significantly lower and the GPS and CONUT score were significantly higher in patients ≥ 75 years (P = 0.035, 0.045, 0.028, 0.049, and 0.028, respectively). Moreover, the treatment rate after recurrence was also significantly lower in older patients (44% in patients ≥ 75 years, 81% in patients < 75 years; P = 0.0091). The median time from RTD in patients aged ≥ 75 years was significantly shorter than that in patients aged < 75 years (0.6 years vs 1.3 years, P = 0.020) (Figure 2). In multivariate analysis, age ≥ 75 years, CONUT score ≥ 4, poorly-differentiated adenocarcinoma or adenosquamous carcinoma, and failure to implement treatment after recurrence were independent risk factors for a short time from RTD (HR: 3.5, 5.3, 4.7, and 5.8, respectively) (Table 4). When assessing outcomes using only age ≥ 75 years and CONUT score ≥ 4, which can be easily assessed preoperatively, recurrent patients with risk scores of 1-2 had a significantly shorter time from RTD than patients with a risk score of zero (median RTD: 0.6 and 1.4 years, P = 0.0016) (Supplemental Figure 1). Furthermore, in multivariate analyses, only age ≥ 75 years (odds ratio: 0.24, P = 0.041) was an independent risk factor for implementation of treatment after recurrence (Table 5). Discussion This study revealed no significant differences in postoperative mortality and morbidity, RFS, DSS, and OS between patients aged ≥ 75 years and those aged < 75 years who underwent PD. In contrast, at the time of recurrence, immuno-inflammatory indexes and nutritional indicators were significantly worse in patients aged ≥ 75 years and the median survival time from RTD was significantly shorter compared to patients aged < 75 years. In addition, age ≥ 75 years was an independent risk factor for not receiving treatment after recurrence. These findings suggest that older patients with recurrence may have a poor general condition due to various factors as well as a shorter RTD due to difficulty in implementing treatment after recurrence. These findings may be useful when considering treatment strategies for older patients with DC. BTC was previously more prevalent in Asia, but its incidence has been increasing worldwide in recent years. 1 – 3 BTC is one of the gastrointestinal cancers with a poor prognosis, and the only curative treatment is surgical resection. However, recurrence is often observed even after radical resection 6 and the 5-year survival rate in patients with BTC after curative resection has been reported to be as low as approximately 20%. 36 In Japan, BTC is the sixth leading cause of cancer-related deaths, accounting for approximately 18 000 deaths per year. 37 The surgical methods for DC, which is a type of BTC, include extrahepatic bile duct resection, PD, and HPD. With regard to the surgery-related complications and prognosis, PD with regional LND is currently the standard surgical procedure for resectable DC. 4 – 6 PD is also used for the treatment of pancreatic head and ampullary carcinomas. Therefore, it is important to investigate the safety and efficacy of PD in older patients. Despite the recent advances in medical technology, PD carries a certain degree of morbidity and mortality. 7 , 8 , 17 – 24 As mentioned earlier, there are conflicting reports regarding the safety and effectiveness of PD in older patients as compared to younger patients. Studies that claimed that PD was as safe in older patients as in younger patients were mainly conducted in high-volume centers that provide high-quality medical care. 17 – 20 Conversely, a real-world large-scale study in Japan revealed that the overall hospital mortality rate after PD was 2.2%, with patients aged 70 years or older having higher postoperative mortality and complication rates, and longer length of postoperative hospital stay than those aged 70 years or younger. 21 Thus, the safety of PD in older patients remains a crucial unresolved issue in these times of expanding life expectancy, as it varies depending on patient background characteristics and study population. In this study, the hospital mortality rate was favorable, and the length of postoperative hospital stay was shorter than that reported in the aforementioned large-scale study, indicating that the results of this study are safer and more reliable. In cases of recurrence after radical resection, multidisciplinary treatment is administered, which mainly comprises drug therapy, but the median OS remains low at approximately 1 year. 4 , 32 , 33 Although recent studies have demonstrated improvement in prognosis of patients undergoing GCD and GCS therapy compared to conventional treatment regimens such as GC therapy, the prognosis remains poor, with a median survival time of approximately 12.8 and 16.2 months with GCD and GCS therapy, respectively. 34 , 35 Most of the previous clinical trials excluded and/or included only a small number of older patients; 32 – 35 therefore, it remains unclear whether the safety and effectiveness of drug therapy is similar between older and younger patients with DC. Previous studies have reported that poor cognitive and physical function and performance status in older patients make it difficult to continue chemotherapy. 38 , 39 However, the initiation and continuation of chemotherapy should take into account multiple factors in addition to age, and the decision to initiate chemotherapy should be based on the patient’s general condition using a numerical index. Immune-inflammatory and nutritional indicators have been reported as predictors of postoperative prognosis and chemotherapy efficacy in some cancers. 14 – 16 These variables can be readily evaluated preoperatively and may be potentially useful for predicting therapeutic treatability after recurrence. To our knowledge, no previous study has examined the efficacy of these indicators in predicting treatment suitability after recurrence in patients with DC. This study examined various indicators and demonstrated that CONUT score is an important patient factor that affects the treatment after recurrence. In recent years, the concept of frailty has been reported as an indicator of the clinical performance status, and a previous study showed that improved prediction of adverse postoperative outcomes in patients with PD by combining frailty with other factors. 40 Although age was identified as a risk factor for a short survival time from RTD and treatment failure after recurrence in this study, age is merely one factor, and there is a need to explore other patient background characteristics, which are currently difficult to quantify. Future studies should aim to elucidate these factors based on various preoperative measurable parameters that influence treatment after recurrence in older patients with DC to aid clinical decision-making regardless of age. In addition, it is necessary to verify whether improving these indicators through pre- and postoperative interventions will lead to extended survival. This study has some limitations. First, over the 24-year study period, patients received different diagnostic tests and treatments, including various chemotherapy regimens and pre-, intra-, and postoperative management plans, owing to advances in these techniques over time. Thus, a selection bias cannot be ruled out, especially for surgical indications and procedures. These variations may have skewed the outcomes of patients treated during different periods of the study. Second, the number of cases and recurrence/death events was insufficient compared to the number of items used in the multivariate analysis. Finally, this was a retrospective study performed at a single institution, which may limit the generalizability of the results. However, this study was conducted as a preliminary pilot study to determine the potential of a larger observational study to clarify the validity of surgical resection in older patients with DC. The results of this study are satisfactory in that they lay the groundwork for further research. In conclusion, we demonstrated that PD in patients with DC aged ≥ 75 years may be tolerated, but the treatment of recurrent disease in these patients is difficult and they have a shorter RTD. Declarations Acknowledgments The authors thank Editage (www.editage.jp) for the English language editing. Disclosure of interest None of the authors has any financial or personal relationships with other people or organizations that could potentially and inappropriately influence (bias) our work and conclusions. Funding statement This research did not receive any specific funding from any agencies in the public, commercial, or not-for-profit areas. Disclosure of statement None of the authors have any financial and personal relationships with other people or organizations that could potentially and inappropriately influence (bias) our work and conclusions. Author Contribution WI, HK, and DI contributed to conception and design. WI, HK, RS, YN, HA, and DI contributed to development of methodology. WI, HK, RS, YN, HA, YH, TN, KT, SM, KT, KS, KS, SF, YK, and DI contributed to development of data acquisition and analysis. WI, HK, and DI contributed to, writing, reviewing, and/or revising of the manuscript. All authors have read, reviewed, and approved the final manuscript. References Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69–90. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002; 3: 10. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma – evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018; 15: 95–111. Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, Ebata T, Konishi M, Sano K, Shimada K, Shimizu H, Higuchi R, Wakai T, Isayama H, Okusaka T, Tsuyuguchi T, Hirooka Y, Furuse J, Maguchi H, Suzuki K, Yamazaki H, Kijima H, Yanagisawa A, Yoshida M, Yokoyama Y, Mizuno T, Endo I. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. J Hepatobiliary Pancreat Sci. 2021; 28: 26-54. Smith AM, Liaskos C, Verbeke CS. Impact of intrapancreatic or extrapancreatic bile duct involvement on survival following pancreatoduodenectomy for common bile duct cancer. Br J Surg. 2014; 101: 89–99. Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A, Valle JW, Ducreux M; ESMO Guidelines Committee. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34: 127-140. Fernandez-del Castillo C, Morales-Oyarvide V, McGrath D, Wargo JA, Ferrone CR, Thayer SP et al. Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery. 2012; 152: S56–S63. Kakeji Y, Takahashi A, Hasegawa H, Ueno H, Eguchi S, Endo I, Sasaki A, Takiguchi S, Takeuchi H, Hashimoto M, Horiguchi A, Masaki T, Marubashi S, Yoshida K, Gotoh M, Konno H, Yamamoto H, Miyata H, Seto Y, Kitagawa Y, National Clinical Database. Surgical outcomes in gastroenterological surgery in Japan: Report of the National Clinical Database 2011-2018. Ann Gastroenterol Surg 2020; 4: 250–274. Rudnicka E, Napoerala P, Podfigurna A, Meczekalski B, Smolarczyk R, Grymowicz M. The World Health Organization (WHO) approach to healthy ageing. Maturitas. 2020; 139: 6-11. Ministry of Health, Labour and Welfare. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.mhlw.go.jp/toukei/saikin/hw/life/tdfk20/dl/tdfk20-10.pdf https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/koukikourei/index.html Lexell J, Taylor CC, Sjöström M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men J Neurol Sci. 1988; 84: 275-94. Strechler BL：Origin and comparison of the feects of time and high-energy radiations on living systems. Quart Rev Biol. 1959; 34: 117-142. Okuno M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma. J Gastroenterol. 2016; 51: 153–161. Takagi K, Yagi T, Umeda Y, Shinoura S, Yoshida R, Nobuoka D, Kuise T, Araki H, Fujiwara T. Preoperative controlling nutritional status (CONUT) score for assessment of prognosis following hepatectomy for hepatocellular carcinoma. World J Surg. 2017; 41: 2353–2360. Shiihara M, Higuchi R, Izumo W, Yazawa T, Uemura S, Furukawa T, Yamamoto M. Impact of the controlling nutritional status score on severe postoperative complications of pancreaticoduodenectomy for pancreatic cancer. Langenbecks Arch Surg. 2021; 406: 1491-1498. Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Matsunaga Y, Shiihara M, Yamamoto M. Evaluation of the validity of pancreatectomy for very elderly patients with pancreatic ductal adenocarcinoma. Langenbecks Arch Surg. 2021; 406: 1081-1092. Sugimachi K, Iguchi T, Mano Y, Nishijima T, Nakanoko T, Uehara H, et al. The impact of immunonutritional and physical status on surgical outcome after pancreaticoduodenectomy in elderly patients. Anticancer Res. 2019; 39: 6347–53. Okabayashi T, Sui K, Murokawa T, Kimura J, Iwata J, Morita S, et al. Indications for pancreaticoduodenectomy affected postoperative outcomes in octogenarians. Ann Gastroenterol Surg. 2021; 5: 102–10. Ikenaga N, Nakata K, Abe T, Ideno N, Fujimori N, Oono T, et al. Risks and benefits of pancreaticoduodenectomy in patients aged 80 years and over. Langenbecks Arch Surg. 2023; 408: 108. Mori Y, Okawara M, Shibao K, Kohi S, Tamura T, Sato N, Fujino Y, Fushimi K, Matsuda S, Hirata K. Short-term outcomes of pancreatoduodenectomy in older individuals over a 9-year period using real-world data: A multilevel analysis based on a nationwide administrative database in Japan. J Hepatobiliary Pancreat Sci. 2024; 31: 262-272. Zhang W, Huang Z, Zhang J, Che X. Safety and effectiveness of open pancreaticoduodenectomy in adults aged 70 or older: a meta-analysis. J Geriatr Oncol. 2021; 12: 1136–45. Shaib WL, Zakka K, Hoodbhoy FN, Belalcazar A, Kim S, Cardona K, et al. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. J Geriatr Oncol. 2020; 11: 660–7. Yuan F, Essaji Y, Belley-Cote EP, Gafni A, Latchupatula L, Ruo L, et al. Postoperative complications in elderly patients following pancreaticoduodenectomy lead to increased postoperative mortality and costs. A retrospective cohort study. Int J Surg. 2018; 60: 204–9 Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare). https://ganjoho.jp/reg_stat/statistics/data/dl/excel/cancer_incidenceNCR(2016-2020).xls Hurwitz, E.E.; Simon, M.; Vinta, S.R.; Zehm, C.F.; Shabot, S.M.; Minhajuddin, A.; Abouleish, A.E. Adding Examples to the ASA-Physical Status Classification Improves Correct Assignment to Patients. Anesthesiology 2017, 126, 614–622 Amin MB, American Joint Committee on Cancer. AJCC cancer staging manual. 8th edn. New York, NY: Springer; 2017. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240: 205-213. Bassi C, Dervenis C, Butturini G, et al, and the International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005; 138: 8-13. Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007; 142: 761-768. Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007; 142: 20-25. Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans TR, Stocken D, Stubbs C, Praseedom R, Ma YT, Davidson B, Neoptolemos J, Iveson T, Cunningham D, Garden OJ, Valle JW, Primrose J; BILCAP study group. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol. 2022; 40: 2048-2057. Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023; 401: 195-203. Ioka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, Seo S, Taketomi A, Takayama T, Yamaue H, Takahashi M, Sho M, Kamei K, Fujimoto J, Toyoda M, Shimizu J, Goto T, Shindo Y, Yoshimura K, Hatano E, Nagano H; Kansai Hepatobiliary Oncology Group (KHBO). Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023; 30: 102-110. Oh D, Ruth HA, Qin S, Chen LT, Okusaka T, Vogel A, et al: Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence. 2022; 1: EVIDoa2200015. Tawarungruang C, Khuntikeo N, Chamadol N, Laopaiboon V, Thuanman J, Thinkhamrop K, et al. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification. BMC Cancer. 2021; 21: 497. chromeextension://efaidnbmnnnibpcajpcglclefindmkaj/https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2024_fig_J.pdf Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, et al (2013) Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase iii study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 31:1464–1470 Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ III, Balducci L (2012) Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 118:3377–3386 Al Abbas AI, Borrebach JD, Pitt HA, Bellon J, Hogg ME, Zeh HJ, 3rd, Zureikat AH. Development of a Novel Pancreatoduodenectomy-Specific Risk Calculator: an Analysis of 10,000 Patients. J Gastrointest Surg. 2021; 25: 1503-1511. Tables Table 1. Preoperative clinicopathological characteristics of the resected patients with distal cholangiocarcinom Age P value ≥ 75 (n=32) < 75 (n=68) Age (years, range) 78 (75-86) 66 (31-74) < 0.001 Sex Male 21 (66%) 52 (76%) 0.26 Preoperative BMI (kg/m 2 , range) 21.4 (16.0-29.3) 21.5 (14.7-41.4) 0.87 Preoperative TP (g/dL, range) 6.9 (5.5-8.4) 6.9 (5.4-8.5) 0.68 Preoperative Alb (g/dL, range) 3.9 (2.1-4.6) 3.8 (2.7-4.9) 0.94 Preoperative TC (mg/dL, range) 172 (93-256) 166 (80-378) 0.34 Preoperative TG (mg/dL, range) 104 (51-178) 108 (43-305) 0.80 Preoperative CRP (mg/dL, range) 0.18 (0.1-2.9) 0.23 (0.1-13.4) 0.092 Preoperative HbA1c (%, range) 5.6 (4.5-7.9) 5.7 (4.4-12.1) 0.15 Preoperative NLR (range) 2.2 (1.1-21.6) 2.5 (0.78-11.7) 0.66 Preoperative PLR (range) 154.0 (64.5-1014.4) 166.7 (66.8-511.1) 0.80 Preoperative LMR (range) 4.3 (0.89-7.7) 4.0 (2.5-10.4) 0.27 Preoperative PNI (range) 44.9 (22.1-58.2) 44.8 (33.1-64.7) 0.93 Preoperative CAR (range) 0.045 (0.022-1.4) 0.059 (0.020-3.9) 0.15 Preoperative GPS score 0 / 1 / 2 23 (71%) / 5 (16%) / 4 (13%) 41 (60%) / 19 (25%) / 10 (15%) 0.49 Preoperative CONUT score < 4 / ≥ 4 22 (69%) / 10 (31%) 46 (67%) / 22 (33%) 0.91 Preoperative CEA (ng/mL, range) 2.3 (0.8-18.5) 2.2 (0.8-45.9) 0.77 Preoperative CA19-9 (U/mL, range) 27.8 (0.6-321) 31.8 (0.6-44000) 0.26 ASA-PS Class 1 / 2 / 3 1 (3%) / 19 (59%) / 12 (38%) 2 (3%) / 47 (69%) / 19 (28%) 0.62 Vascular resection With 2 (6%) 3 (4%) 0.70 Number of dissected lymph node (range) 8 (2-43) 11 (0-36) 0.79 Operative time (min, range) 447 (256-720) 481 (293-724) 0.17 Blood loss (ml, range) 532 (133-2312) 673 (247-2831) 0.51 Pathological type wel / mod / por / ase 11 (34%) / 14 (44%) / 5 (16%) / 2 (6%) 34 (50%) / 22 (32%) / 11 (16%) 1 (1%) 0.32 Stage Ⅰ / ⅡA / ⅡB / ⅢA / ⅢB 4 (13%) / 13 (40%) / 11 (34%) / 4 (13%) / 0 (0%) 7 (10%) / 25 (37%) / 28 (41%) / 7 (10%) / 1 (2%) 0.86 Residual tumor R0 27 (84%) 46 (68%) 0.069 Postoperative complication grade ≥ Ⅲ 12 (38%) 21 (31%) 0.55 POPF B or C 10 (33%) 18 (26%) 0.62 DGE B or C 3 (9%) 8 (12%) 0.72 PPH B or C 1 (3%) 0 (0%) 0.13 Adjuvant chemotherapy With 5 (16%) 12 (17%) 0.80 Postoperative hospital stay (day, range) 28 (9-71) 27 (9-76) 0.84 Recurrence Liver Lymph node Local recurrence Lung Dissemination 16 (50%) 9 (56%) 6 (38%) 4 (25%) 1 (6%) 3 (19%) 36 (53%) 11 (31%) 11 (31%) 9 (25%) 7 (19%) 4 (11%) 0.78 0.081 0.62 1.00 0.19 0.47 Dead from distal cholangiocarcinoma 12 (38%) 26 (38%) 0.94 Dead from another disease 5 (16%) 8 (12%) 0.60 Postoperative observation period (year, range) 2.2 (0.2-14.7) 3.5 (0.28-20.0) 0.10 In hospital mortality 0 (0%) 0 (0%) N.A Abbreviations: BMI: body mass index, TP: total protein, Alb: albumin, TC: total cholesterol, TG: triglyceride, CRP: C-reactive protein, HbA1c: hemoglobin A1c, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, LMR: Lymphocyte/Monocyte ratio, PNI: prognostic nutrition index, CAR: C-reactive protein-albumin ratio, GPS: glasgow prognostic score, CONUT: controlling nutritional status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, ASA-PS: American society of anesthesiologists-physical status, PD: pancreaticoduodenectomy, EHBD: extrahepatic bile duct resection, wel: well differentiated adenocarcinoma, mod: moderately differentiated adenocarcinoma, por: poorly differentiated adenocarcinoma, asc: adenosquamous carcinoma, POPF: postoperative pancreatic fistula grade, DGE: delayed gastric empty grade, PPH: post-pancreatectomy hemorrhage, N.A: not avaivalbe Table 2. Univariate and multivariate analyses of prognostic factors for overall survival in resected patients with distal cholangiocarcinoma Univariate Multivariate Prognostic factors Definition n OS P value Hazard ratio (95% CI) P value 3-years 5-years Age (years) < 75 68 55.0 55.0 0.34 ≥ 75 32 67.6 58.5 Preoperative BMI (kg/m 2 ) ≥ 22.1 42 71.1 63.1 0.21 < 22.1 58 58.9 48.2 Preoperative TP (g/dL) ≥ 6.6 79 67.6 58.4 0.057 < 6.6 21 49.1 36.8 Preoperative Alb (g/dL) ≥ 3.5 76 71.9 59.0 0.011 1.0 0.72 < 3.5 24 38.5 38.5 1.3 (0.29-5.9) Preoperative TC (mg/dL) ≥ 198 36 83.0 75.9 0.014 1.0 0.21 < 198 64 52.1 40.3 1.6 (0.75-3.6) Preoperative TG (mg/dL) ≥ 104 55 73.7 66.3 0.0077 1.0 0.90 < 104 45 51.2 37.7 1.1 (0.51-2.1) Preoperative CRP (mg/dl) < 0.28 54 74.5 66.0 0.018 1.0 0.77 ≥ 0.28 46 50.9 40.5 1.3 (0.23-7.2) Preoperative HbA1c (%) < 7.0 88 64.9 55.5 0.79 ≥ 7.0 12 56.3 42.2 Preoperative NLR < 2.34 50 65.3 62.4 0.094 ≥ 2.34 50 62.4 46.9 Preoperative PLR < 131.2 33 73.8 73.8 0.025 1.0 0.95 ≥ 131.2 67 58.9 45.3 1.1 (0.41-2.6) Preoperative LMR ≥ 2.97 80 67.7 60.2 0.0071 1.0 0.16 < 2.97 20 50.0 35.0 2.0 (0.76-5.2) Preoperative PNI ≥ 40.5 78 72.6 63.4 < 0.001 1.0 0.47 < 40.5 22 34.3 22.8 1.6 (0.46-5.4) Preoperative CAR < 0.054 86 75.7 65.7 0.028 1.0 0.97 ≥ 0.054 14 52.8 43.5 1.1 (0.21-5.0) Preoperative GPS score 0-1 86 67.5 55.8 0.041 1.0 0.62 2 14 42.9 42.9 1.5 (0.32-6.8) Preoperative CONUT score 0-3 68 74.8 66.2 < 0.001 1.0 0.0064 ≥ 4 32 41.0 29.4 4.9 (1.5-15.4) Preoperative CEA (ng/mL) < 10.5 96 64.5 54.1 0.80 ≥ 10.5 4 50.0 50.0 Preoperative CA19-9 (U/mL) < 95.7 22 67.2 56.3 0.082 ≥ 95.7 78 51.7 45.9 ASA-PS Class 1-2 69 69.5 63.8 0.0045 1.0 0.88 Class 3 31 50.6 29.5 1.1 (0.52-2.1) Vascular resection Without 95 66.3 55.9 0.029 1.0 0.17 With 5 20.0 20.0 2.5 (0.68-9.3) Postoperative complication ≤ Ⅱ 67 66.6 53.3 0.50 ≥ Ⅲ 33 57.1 53.0 POPF None or BL 72 66.6 54.5 0.40 B or C 28 57.0 52.2 DGE None or A 89 65.4 54.3 0.59 B or C 11 50.0 50.0 Pathological type wel + mod 81 73.3 62.6 < 0.001 1.0 0.011 por + asc 19 26.3 21.1 2.8 (1.3-6.3) T factor T 1-2 73 71.6 58.9 0.0069 1.0 0.20 T 3-4 27 44.4 40.4 1.7 (0.76-3.6) Lymph node metastasis Negative 55 70.7 63.1 0.0071 1.0 0.023 Positive 45 55.3 42.7 3.6 (1.2-11.0) Residual tumor R0 73 69.4 59.3 0.0084 1.0 0.017 R1 27 49.4 41.2 2.4 (1.2-4.9) Adjuvant chemotherapy With 17 63.0 47.3 0.66 Without 83 63.6 54.3 Abbreviations: OS: overall survival rate, CI: confidence interval, BMI: body mass index, TP: total protein, Alb: albumin, TC: total cholesterol, TG: triglyceride, CRP: C-reactive protein, HbA1c: hemoglobin A1c, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, LMR: Lymphocyte/Monocyte ratio, PNI: prognostic nutrition index, CAR: C-reactive protein-albumin ratio, GPS: glasgow prognostic score, CONUT: controlling nutritional status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, ASA-PS: American society of anesthesiologists-physical status, wel: well differentiated adenocarcinoma, mod: moderately differentiated adenocarcinoma, por: poorly differentiated adenocarcinoma, asc: adenosquamous carcinoma, POPF: postoperative pancreatic fistula grade, BL: biochemical leak, DGE: delayed gastric empty grade Table 3. Clinicopathological characteristics of the recurrent patients at the time of recurrence Age P value ≥ 75 (n=16) < 75 (n=36) Age at the time of first surgery (years, range) 78 (75-86) 69 (31-74) < 0.001 Sex Male 8 (50%) 30 (83%) 0.015 TP at the time of recurrence (g/dL, range) 6.7 (6.0-7.6) 6.8 (5.8-7.7) 0.66 Alb at the time of recurrence (g/dL, range) 3.5 (2.4-4.2) 3.8 (2.1-4.7) 0.035 TC at the time of recurrence (mg/dL, range) 140 (66-238) 147 (99-266) 0.83 TG at the time of recurrence (mg/dL, range) 90 (45-158) 91 (41-277) 0.64 CRP at the time of recurrence (mg/dL, range) 0.43 (0.1-9.9) 0.14 (0.1-18.9) 0.92 NLR at the time of recurrence (range) 2.7 (0.76-8.9) 2.2 (0.68-17.8) 0.56 PLR at the time of recurrence (range) 170.2 (71.3-368.8) 165.5 (22.4-377.5) 0.27 LMR at the time of recurrence (range) 2.8 (0.82-5.8) 4.1 (1.0-9.3) 0.045 PNI at the time of recurrence (range) 39.0 (28.4-51.6) 44.9 (29.6-53.1) 0.028 CAR at the time of recurrence (range) 0.14 (0.024-4.1) 0.041 (0.023-7.8) 0.92 GPS score at the time of recurrence 0-1 / 2 6 (37%) / 10 (63%) 24 (67%) / 12 (33%) 0.049 CONUT score at the time of recurrence 0-4 / ≥ 5 8 (50%) / 8 (50%) 29 (81%) / 7 (19%) 0.028 CEA at the time of recurrence (ng/mL, range) 4.0 (1.4-41.9) 3.9 (0.7-17.4) 0.14 CA19-9 at the time of recurrence (U/mL, range) 113.5 (5.1-1856) 51.7 (5.5-1162) 0.11 Pathological type wel or mod / por or asc 11 (69%) / 5 (31%) 27 (75%) / 9 (25%) 0.64 Treatment after recurrence With Chemotherapy Radiation Surgical resection 7 (44%) 8 (100%) 0 (0%) 0 (0%) 29 (81%) 27 (92%) 1 (4%) 1 (4%) 0.0091 Dead from distal cholangiocarcinoma 11 (69%) 23 (64%) 0.73 Dead from another disease 0 (0%) 2 (12%) 0.60 Abbreviations: TP: total protein, Alb: albumin, TC: total cholesterol, TG: triglyceride, CRP: C-reactive protein, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, LMR: Lymphocyte/Monocyte ratio, PNI: prognostic nutrition index, CAR: C-reactive protein-albumin ratio, GPS: glasgow prognostic score, CONUT: controlling nutritional status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, wel: well differentiated adenocarcinoma, mod: moderately differentiated adenocarcinoma, por: poorly differentiated adenocarcinoma, asc: adenosquamous carcinoma Table 4. Univariate and multivariate analyses of risk factors for short time from recurrence to death in recurrent patients with distal cholangiocarcinoma Univariate Multivariate Prognostic factors Definition n Median RTD (years) (95% CI) P value Hazard ratio (95% CI) P value Age at the time of first surgery (years) < 75 36 1.3 (0.74-1.7) 0.020 1.0 0.022 ≥ 75 16 0.52 (0.17-1.0) 3.5 (1.2-9.9) TP at the time of recurrence (g/dL) ≥ 6.6 37 1.0 (0.73-2.5) 0.081 < 6.6 15 0.73 (0.17-1.4) Alb at the time of recurrence (g/dL) ≥ 3.5 33 1.0 (0.74-1.7) 0.048 1.0 0.52 < 3.5 19 0.64 (0.20-1.4) 1.7 (0.35-8.0) TC at the time of recurrence (mg/dL) ≥ 198 7 1.4 (0.44-2.5) 0.44 < 198 45 0.99 (0.64-1.3) TG at the time of recurrence (mg/dL) ≥ 104 19 1.0 (0.64-2.5) 0.82 < 104 33 1.0 (0.51-1.7) CRP at the time of recurrence (mg/dL) < 0.28 27 1.3 (0.68-2.5) 0.074 ≥ 0.28 25 0.77 (0.51-1.4) NLR at the time of recurrence < 2.34 28 1.3 (1.0-2.0) 0.031 1.0 0.14 ≥ 2.34 24 0.68 (0.44-0.99) 1.8 (0.82-4.1) PLR at the time of recurrence < 131.2 17 4.3 (0.51-NA) 0.026 1.0 0.24 ≥ 131.2 35 0.77 (0.61-1.3) 1.8 (0.82-4.1) LMR at the time of recurrence ≥ 2.97 36 1.3 (0.73-2.0) 0.028 1.0 0.45 < 2.97 16 0.64 (0.14-0.99) 1.5 (0.5-4.1) PNI at the time of recurrence ≥ 40.5 33 1.4 (0.74-2.5) 0.0029 1.0 0.93 < 40.5 19 0.61 (0.24-0.99) 1.1 (0.16-7.7) CAR at the time of recurrence < 0.054 25 1.4 (0.73-3.3) 0.017 1.0 0.35 ≥ 0.054 27 0.74 (0.51-1.3) 1.7 (0.55-5.5) GPS score at the time of recurrence 0-1 44 1.0 (0.73-1.5) 0.039 1.0 0.84 2 8 0.55 (0.072-2.0) 1.1 (0.30-4.4) CONUT score at the time of recurrence 0-3 30 1.4 (0.99-2.5) 0.0053 1.0 0.030 ≥ 4 22 0.61 (0.32-1.0) 5.3 (1.2-23.5) CEA at the time of recurrence (ng/mL) < 10.5 48 1.0 (0.68-1.5) 0.011 1.0 0.43 ≥ 10.5 4 0.5 (0.14-0.73) 1.8 (0.40-8.5) CA19-9 at the time of recurrence (U/mL) < 95.7 31 1.4 (0.64-2.5) 0.030 1.0 0.96 ≥ 95.7 21 0.88 (0.44-1.3) 1.0 (0.40-2.6) Pathological type wel + mod 38 0.57 (0.24-1.1) 0.019 1.0 < 0.001 por + asc 14 1.3 (0.74-2.0) 4.7 (2.0-11.2) T factor T 1-2 34 1.3 (0.73-1.7) 0.33 T 3-4 18 0.69 (0.26-1.4) Lymph node metastasis Negative 21 1.3 (0.51-1.7) 0.84 Positive 31 1.0 (0.61-1.4) Residual tumor R0 34 1.0 (0.64-2.0) 0.23 R1 18 1.0 (0.51-1.7) Adjuvant chemotherapy With 12 1.4 (0.73-2.5) 0.19 Without 40 0.99 (0.53-1.7) Implementation of treatment after recurrence Implemented 36 1.3 (1.0-2.5) < 0.001 1.0 < 0.001 Not implemented 16 0.41 (0.14-0.64) 5.8 (2.1-15.7) Abbreviations: RTD: time from recurrence to death, CI: confidence interval, TP: total protein, Alb: albumin, TC: total cholesterol, TG: triglyceride, CRP: C-reactive protein, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, LMR: Lymphocyte/Monocyte ratio, PNI: prognostic nutrition index, CAR: C-reactive protein-albumin ratio, GPS: glasgow prognostic score, CONUT: controlling nutritional status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, wel: well differentiated adenocarcinoma, mod: moderately differentiated adenocarcinoma, por: poorly differentiated adenocarcinoma, asc: adenosquamous carcinoma Table 5. Univariate and multivariate analyses of risk factors for implementation of treatment after recurrence in patients with disease recurrence Univariate Multivariate Prognostic factors Definition n Implement of treatment OR (95% CI) P value OR (95% CI) P value Age at the time of first surgery (years) < 75 36 29 (81%) 1.0 0.011 1.0 0.041 ≥ 75 16 7 (44%) 0.19 (0.052-0.68) 0.24 (0.062-0.94) TP at the time of recurrence (g/dL) ≥ 6.6 37 29 (79%) 1.0 0.077 < 6.6 15 8 (53%) 0.32 (0.088-1.1) Alb at the time of recurrence (g/dL) ≥ 3.5 33 26 (79%) 1.0 0.11 < 3.5 19 11 (58%) 0.37 (0.11-1.3) TC at the time of recurrence (mg/dL) ≥ 198 7 7 (100%) 1.0 N.A < 198 45 30 (67%) N.A TG at the time of recurrence (mg/dL) ≥ 104 19 16 (84%) 1.0 0.12 < 104 33 21 (64%) 0.33 (0.079-1.4) CRP at the time of recurrence (mg/dL) < 0.28 27 21 (78%) 1.0 0.28 ≥ 0.28 25 16 (64%) 0.51 (0.15-1.7) NLR at the time of recurrence < 2.34 28 23 (82%) 1.0 0.065 ≥ 2.34 24 14 (58%) 0.30 (0.086-1.1) PLR at the time of recurrence < 131.2 17 14 (82%) 1.0 0.22 ≥ 131.2 36 23 (66%) 0.41 (0.098-1.7) LMR at the time of recurrence ≥ 2.97 36 27 (75%) 1.0 0.36 < 2.97 16 10 (63%) 0.56 (0.16-2.0) PNI at the time of recurrence ≥ 40.5 33 27 (82%) 1.0 0.030 1.0 0.24 < 40.5 19 10 (53%) 0.25(0.070-0.87) 0.24 (0.022-2.6) CAR at the time of recurrence < 0.054 25 20 (80%) 1.0 0.18 ≥ 0.054 27 17 (63%) 0.43 (0.12-1.5) GPS score at the time of recurrence 0-1 44 32 (73%) 1.0 0.56 2 8 5 (63%) 0.63 (0.13-3.0) CONUT score at the time of recurrence 0-3 30 25 (83%) 1.0 0.028 1.0 0.94 ≥ 4 22 12 (55%) 0.24 (0.067-0.86) 0.92 (0.084-10.0) CEA at the time of recurrence (ng/mL) < 10.5 48 37 (77%) 1.0 N.A ≥ 10.5 4 0 (0%) N.A CA19-9 at the time of recurrence (U/mL) < 95.7 31 22 (71%) 1.0 0.97 ≥ 95.7 21 15 (71%) 1.0 (0.30-3.5) Adjuvant chemotherapy With 12 11 (92%) 1.0 0.10 Without 43 26 (65%) 0.17 (0.020-1.4) Abbreviations: OR: odds ratio, CI: confidence interval, TP: total protein, Alb: albumin, TC: total cholesterol, N.A: not available, TG: triglyceride, CRP: C-reactive protein, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, LMR: Lymphocyte/Monocyte ratio, PNI: prognostic nutrition index, CAR: C-reactive protein-albumin ratio, GPS: glasgow prognostic score, CONUT: controlling nutritional status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, wel: well differentiated adenocarcinoma, mod: moderately differentiated adenocarcinoma, por: poorly differentiated adenocarcinoma, asc: adenosquamous carcinoma Additional Declarations No competing interests reported. Supplementary Files Supplemental.docx Cite Share Download PDF Status: Published Journal Publication published 03 Apr, 2025 Read the published version in Langenbeck's Archives of Surgery → Version 1 posted Editorial decision: Revision requested 10 Feb, 2025 Reviews received at journal 28 Jan, 2025 Reviewers agreed at journal 26 Jan, 2025 Reviewers agreed at journal 26 Jan, 2025 Reviews received at journal 24 Jul, 2024 Reviewers agreed at journal 14 Jul, 2024 Reviewers invited by journal 12 Jul, 2024 Editor assigned by journal 10 Jul, 2024 Submission checks completed at journal 08 Jul, 2024 First submitted to journal 04 Jul, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4688865","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":333466202,"identity":"955701e6-1103-410b-8697-9e4075e74230","order_by":0,"name":"Wataru Izumo","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Wataru","middleName":"","lastName":"Izumo","suffix":""},{"id":333466205,"identity":"6ae707bd-40dd-4054-811b-17e65a1f904f","order_by":1,"name":"Hiromichi Kawaida","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Hiromichi","middleName":"","lastName":"Kawaida","suffix":""},{"id":333466206,"identity":"38a9b27f-3e2b-4b01-aa2e-a7115f7bb730","order_by":2,"name":"Ryo Saito","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ryo","middleName":"","lastName":"Saito","suffix":""},{"id":333466208,"identity":"29887478-3591-49ff-8578-61cd4c44efd3","order_by":3,"name":"Yuki Nakata","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Yuki","middleName":"","lastName":"Nakata","suffix":""},{"id":333466209,"identity":"51718213-5020-4598-a3e8-9296912b4355","order_by":4,"name":"Hidetake Amemiya","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Hidetake","middleName":"","lastName":"Amemiya","suffix":""},{"id":333466210,"identity":"cc0d6e35-ec40-43c0-b30e-83178370f7c3","order_by":5,"name":"Yudai Higuchi","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Yudai","middleName":"","lastName":"Higuchi","suffix":""},{"id":333466212,"identity":"45fff209-6584-40d2-9822-64024475b6ad","order_by":6,"name":"Takashi Nakayama","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Takashi","middleName":"","lastName":"Nakayama","suffix":""},{"id":333466214,"identity":"59a26926-174a-40b9-a47f-7be4a675ce40","order_by":7,"name":"Kazunori Takahashi","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Kazunori","middleName":"","lastName":"Takahashi","suffix":""},{"id":333466216,"identity":"5af2d0a5-5d34-43cd-8076-e67a77829044","order_by":8,"name":"Suguru Maruyama","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Suguru","middleName":"","lastName":"Maruyama","suffix":""},{"id":333466218,"identity":"acfe7c0d-cc9f-4464-aac4-1d8c0cab5156","order_by":9,"name":"Koichi Takiguchi","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Koichi","middleName":"","lastName":"Takiguchi","suffix":""},{"id":333466221,"identity":"8268a1f4-539d-4f57-83c1-649077be69fb","order_by":10,"name":"Katsutoshi Shoda","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Katsutoshi","middleName":"","lastName":"Shoda","suffix":""},{"id":333466228,"identity":"60dd7732-eccd-4167-a7a1-fefe5ed8194b","order_by":11,"name":"Kensuke Shiraishi","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Kensuke","middleName":"","lastName":"Shiraishi","suffix":""},{"id":333466234,"identity":"f1d5d5d4-0bd4-4a85-9d29-24f70a1c032a","order_by":12,"name":"Shinji Furuya","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Shinji","middleName":"","lastName":"Furuya","suffix":""},{"id":333466238,"identity":"c29aa0b4-8229-4fdd-8ba1-e6980bf36a95","order_by":13,"name":"Yoshihiko Kawaguchi","email":"","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":false,"prefix":"","firstName":"Yoshihiko","middleName":"","lastName":"Kawaguchi","suffix":""},{"id":333466240,"identity":"8f72a431-0859-4652-ac9c-27c36970d770","order_by":14,"name":"Daisuke Ichikawa","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABFklEQVRIiWNgGAWjYDCCwwxsDAkHgAz2BqiIBCOYxUxYC88BYrUcAGphAKmWSIBpIeAuvuPMzx48OGOX2D/zjeGnGzV35OVnNzcw/KhhYDfHoUXyMJu5QcKN5MQZt3OMpXOOPTPccOdgA2PPMQZmywbsWgwO87BJJHxgzm24nWMgncN2mHGDRGIDA28DA7PBAbxa6nPn3zxj/Dvn32H7+TMSGxj/EtRy43Duhhs8ZtK5bYcTG24kNjDjswXoFzOJhDPH6zeeSSuzzu07nLwBqOWwzDEJnH7hO3/4meSPY9XGcscPb76d8+2w7fwZ6Q8fvqmxScYVYkiAwwDOBDpJItkAt1IYYH+AwrUjQssoGAWjYBSMDAAAzp1lpktszG8AAAAASUVORK5CYII=","orcid":"","institution":"University of Yamanashi Hospital","correspondingAuthor":true,"prefix":"","firstName":"Daisuke","middleName":"","lastName":"Ichikawa","suffix":""}],"badges":[],"createdAt":"2024-07-05 01:08:17","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4688865/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4688865/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s00423-025-03694-9","type":"published","date":"2025-04-03T15:57:03+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":62139313,"identity":"5f525905-7160-48d2-8b9a-180d0e59a7d3","added_by":"auto","created_at":"2024-08-09 16:53:16","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":16495,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan–Meier analyses of overall survival time in resected patients with distal cholangiocarcinoma according to their ages\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-4688865/v1/01a36e56b430021354e499b0.png"},{"id":62140136,"identity":"1a14263c-a473-4658-b95e-5f6a72ac0eb9","added_by":"auto","created_at":"2024-08-09 17:01:16","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":18935,"visible":true,"origin":"","legend":"\u003cp\u003eKaplan–Meier analyses of survival time from recurrence to death in resected patients with distal extrahepatic bile duct carcinoma according to their ages\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-4688865/v1/6399d051524d02e4b1e147a2.png"},{"id":80082236,"identity":"39e83121-99e9-4020-9d1a-3b593aeaa00a","added_by":"auto","created_at":"2025-04-07 16:07:47","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1282265,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4688865/v1/f853005d-2e6c-4aa8-91b1-1b5ae421bbf7.pdf"},{"id":62139315,"identity":"8c11e3f8-dad7-41e8-86c8-2aaba7fc8436","added_by":"auto","created_at":"2024-08-09 16:53:16","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":40593,"visible":true,"origin":"","legend":"","description":"","filename":"Supplemental.docx","url":"https://assets-eu.researchsquare.com/files/rs-4688865/v1/4003b5824ed4f8ab86d23daf.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Evaluation of the validity of pancreatoduodenectomy in older patients with distal cholangiocarcinoma in terms of recurrence","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAlthough the incidence of biliary tract carcinoma (BTC) is higher in parts of Asia and South America, its incidence has been increasing in Europe and the United States.\u003csup\u003e\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e Based on the anatomical site of origin, BTC is classified into intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, gallbladder carcinoma, distal cholangiocarcinoma (DC), and ampullary carcinoma, and each type is thought to have different biological characteristics and malignancy grades.\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e Radical surgical resection is the only curative treatment option for patients with BTC regardless of the anatomical site of origin and pancreatoduodenectomy (PD) with regional lymph node dissection (LND) is the standard operative procedure for DC.\u003csup\u003e\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e In recent years, advances in surgical techniques and pre- and postoperative management have improved the safety of PD,\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e and the number of patients undergoing PD has been rising in Japan.\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e However, PD remains one of the operative procedures with the highest risk of complications and surgery-related mortality rates among all gastrointestinal surgeries;\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e therefore, the indications for PD should be carefully considered.\u003c/p\u003e \u003cp\u003eRecent advances in medical technology have extended the life expectancy worldwide,\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e and the number of older people requiring medical interventions is increasing. The decision regarding whether to provide aggressive medical treatment to older people is complex and involves a variety of factors, including social, economic, and ethical considerations. Furthermore, there is no universal definition of older people or the \u0026ldquo;elderly.\u0026rdquo; Japan is one of the countries with the longest life expectancy.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e People aged 75 years or older are considered \"Late-stage elderly\" and are covered by a medical insurance system which is different from that covering people aged under 75 years.\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e However, this is merely a systemic categorization and does not convey the essential meaning of \"elderly.\"\u003c/p\u003e \u003cp\u003eHowever, surgery in older patients is associated with certain risks because of decrease in tissue fragility, muscle strength, cardiopulmonary function, and physiological reserve capacity with age.\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e,\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e Therefore, while it is considered unacceptable to withhold treatment solely because of age, it is an important factor influencing treatment selection. In addition, although immune inflammatory markers and nutritional indices have been reported to affect the prognosis of patients with various gastroenterological diseases,\u003csup\u003e\u003cspan additionalcitationids=\"CR15\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e their role as prognostic predictors in older people remains unclear.\u003c/p\u003e \u003cp\u003eSome studies have reported that the safety and effectiveness of PD in older patients are equivalent to those in younger patients,\u003csup\u003e\u003cspan additionalcitationids=\"CR18 CR19\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e while other studies have claimed that they are inferior,\u003csup\u003e\u003cspan additionalcitationids=\"CR22 CR23\" citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e and no definite conclusion has been reached yet. In particular, PD is used for the surgical treatment of carcinoma of the pancreatic head as well as DC. Nevertheless, the prevalence of BTC in patients aged 75 years or older is reportedly higher than that of pancreatic cancer (67.9% vs 55.4%).\u003csup\u003e25\u003c/sup\u003e The oncological significance of PD in older patients with DC remains unclear. Furthermore, postoperative treatment and treatment after recurrence are predicted to be difficult in older patients with DC; however, to our knowledge, no studies have compared these factors between older and younger patients with DC. This study aimed to clarify the surgical and oncological validity of PD in older patients with DC, with a focus on recurrence. Large-scale observational studies are required to confirm the findings of this preliminary pilot study.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy design\u003c/h2\u003e \u003cp\u003e This study was approved by the institutional review board of Yamanashi University (approval number: H30906). The requirement for informed consent was waived owing to the retrospective nature of the study.\u003c/p\u003e \u003cp\u003eBetween 2000 and 2023, 143 patients underwent surgical resection of DC at the Department of Digestive Surgery, University of Yamanashi Hospital. We excluded patients who underwent hepatopancreatoduodenectomy (HPD), extrahepatic bile duct resection and reconstruction, residual tumor (R2) resection, and those with an unknown examination status. Finally, 100 patients who underwent curative PD for DC were analyzed retrospectively.\u003c/p\u003e \u003cp\u003eWe evaluated the following clinicopathological parameters and their association with recurrence, time from recurrence to death (RTD), and outcomes. Preoperative parameters included age, sex, body mass index, serum levels of total protein, albumin, total cholesterol, triglyceride, C-reactive protein, hemoglobin A1c, neutrophil-to lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), prognostic nutrition index (PNI), C-reactive protein/albumin ratio, Glasgow prognostic score (GPS), controlling nutritional status (CONUT) score, carcinoembryonic antigen, carbohydrate antigen 19\u0026thinsp;\u0026minus;\u0026thinsp;9 (CA19-9), and American society of anesthesiologists-physical status.\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e Intraoperative parameters comprised vascular resection, number of LND, duration of surgery, and amount of blood loss, while postoperative parameters included pathological type, local invasion, vascular invasion, lymph node metastasis (LNM), existence of residual tumor, postoperative complication grade, postoperative pancreatic fistula (POPF), delayed gastric emptying (DGE), post- pancreatectomy hemorrhage (PPH), completion of adjuvant chemotherapy, length of postoperative hospital stay, hospital mortality, recurrence, implementation of treatment after recurrence, cause of death, and prognosis.\u003c/p\u003e \u003cp\u003eMultivariate analyses of recurrence-free survival (RFS), RTD, disease-specific survival (DSS), and overall survival (OS) were performed by incorporating the above factors.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eSurgical procedure\u003c/h2\u003e \u003cp\u003ePD was performed if the patient expressed a wish to undergo PD and if it was medically indicated, after considering the patient\u0026rsquo;s comorbid status. In patients who underwent PD, the LND region included the area in the hepatoduodenal ligament, area around the common hepatic artery, celiac artery, and superior mesenteric artery, as well as the anterior and posterior surface of the pancreatic head. Portal vein and superior mesenteric vein resections were performed in patients with confirmed or suspected invasion or infiltration of these vessels. The decision regarding the extent of LND and vascular resection was ultimately made at the discretion of the surgeon, while taking into account the patient\u0026rsquo;s condition and age.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eDefinitions\u003c/h2\u003e \u003cp\u003ePreoperative laboratory and imaging data were acquired within 1 month of surgery, while laboratory data were measured after biliary decompression with the total bilirubin level\u0026thinsp;\u0026lt;\u0026thinsp;3.0 mg/dL. The final stage of DC was pathologically defined using the eighth edition of the Union for International Cancer Control criteria.\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e Postoperative complications were rated according to the Clavien-Dindo classification,\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e while POPF, DGE, and PPH were defined according to the International Study Group of Pancreatic Surgery.\u003csup\u003e\u003cspan additionalcitationids=\"CR30\" citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e The cut-off values for the above factors were determined using receiver operating characteristic (ROC) analysis and designated as the point at which the area under the ROC curve was the largest.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eAdjuvant chemotherapy\u003c/h2\u003e \u003cp\u003eAdjuvant chemotherapy was administered for 6 months as a standard practice in patients with stage\u0026thinsp;\u0026ge;\u0026thinsp;I whose general post-surgical condition was stable. Ultimately, the decision to give adjuvant chemotherapy was based on the physician\u0026rsquo;s and patient\u0026rsquo;s choice. Adjuvant chemotherapy was previously performed with a variety of regimens at our institute; however, in this study, adjuvant chemotherapy was defined as treatment with capecitabine or S-1 after 2019, when evidence was established.\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e,\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e In this study, adjuvant chemotherapy was defined to include only patients who were initiated within 10 weeks after surgery and received more than 80% of the planned dose.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eFollow-up\u003c/h2\u003e \u003cp\u003eAll patients underwent laboratory examinations, including for tumor markers every 1\u0026ndash;3 months for the first 3 years and every 3\u0026ndash;6 months after 3\u0026ndash;5 years postoperatively, whereas imaging studies were performed every 3 months for the first 3 years and every 3\u0026ndash;6 months for 3\u0026ndash;5 years postoperatively. RFS was calculated from the time of surgery until recurrence, whereas RTD was calculated from the time of recurrence until death or the last follow-up date. Short RTD was defined as death within six months of recurrence. OS was calculated from the time of surgery until death or the last follow-up date.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eRecurrence\u003c/h2\u003e \u003cp\u003eRecurrence was defined as the presence of a tumor on postoperative imaging studies. When two or more sites of recurrence were observed simultaneously, all of the sites were counted. An increase in the tumor marker levels only was not defined as a recurrence in this study. Local recurrence was defined as locoregional recurrence, including that in the nerve plexus. Lymph node recurrence was defined as an increase in the number of nodes on imaging studies. Liver or lung recurrence was defined as a liver or lung mass detected on imaging studies. Peritoneal dissemination recurrence was defined as the detection of an abdominal mass with ascites or peritoneal thickening.\u003c/p\u003e \u003cdiv id=\"Sec9\" class=\"Section3\"\u003e \u003ch2\u003eTreatment after recurrence\u003c/h2\u003e \u003cp\u003eThe first treatment administered after recurrence was designated as the treatment after recurrence. In this study, only surgical resection, radiation, or drug therapy were included in treatment after recurrence. Drug therapy included only gemcitabine alone, S-1 alone, gemcitabine plus S-1, gemcitabine plus cisplatin (GC), GC plus S-1 (GCS), or GC plus durvalumab (GCD).\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e,\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u003c/sup\u003e Treatment administered to alleviate symptoms alone was not included in treatment after recurrence. Implementation of treatment after recurrence was defined as at least one treatment after recurrence. Ultimately, the decision to undergo treatment after recurrence was based on the physician\u0026rsquo;s and patient\u0026rsquo;s choice.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eUnivariate and multivariate analyses were performed to determine the independent predictors of RTD, DSS, and OS. Survival analyses were performed using the Kaplan-Meier method, log-rank test, and Cox proportional hazards model. Only the factors that were significant in the univariate analysis were subjected to multivariate analysis. Statistical significance was set at P\u0026thinsp;\u0026lt;\u0026thinsp;0.05. All analyses were performed using JMP 17.0.0 for Windows (SAS Institute Inc., Cary, NC, USA).\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003eThe preoperative patient characteristics are shown in Table 1. In this study, 32% of the patients were\u0026nbsp;aged\u0026nbsp;≥ 75 years and 68% were aged \u0026lt; 75 years.\u0026nbsp;There were no significant differences in the pre-, intra-, and postoperative factors other than age, including the levels of various immune-inflammatory markers, nutritional index, frequency of postoperative\u0026nbsp;complications, mortality rates, duration of postoperative hospital stay, and completion of adjuvant chemotherapy\u0026nbsp;between the two groups.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eRecurrence rate, RFS, DSS, and OS\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe recurrence rate was 52% (52/100) in all patients; 50% (16/32) in\u0026nbsp;patients\u0026nbsp;aged\u0026nbsp;≥ 75 years and 53% (36/68) in patients aged \u0026lt; 75 years, with no significant difference between the two groups (P = 0.78).\u0026nbsp;The recurrence sites (with duplication) were\u0026nbsp;mainly the liver (20 patients, 38%), followed by the lymph nodes (17 patients, 33%), local recurrence (13 patients, 25%), lungs (eight patients, 15%),\u0026nbsp;and dissemination (seven patients, 13%).\u0026nbsp;There were no significant differences in the 5-year RFS, DSS, and OS between the two groups (44.5, 61.5, and 55.0% in patients ≥ 75 years; 48.7%, 63.0%, and 58.5% in patients \u0026lt; 75 years; P = 0.81, 0.57, and 0.34, respectively) (Figure 1).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003ePoor prognostic factors in resected patients\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn multivariate analyses, a preoperative CONUT score\u0026nbsp;≥\u0026nbsp;4,\u0026nbsp;poorly-differentiated adenocarcinoma or adenosquamous carcinoma,\u0026nbsp;existence of LNM, and\u0026nbsp;residual tumor (R1 resection) were poor prognostic factors for OS (hazard ratio\u0026nbsp;[HR]: 4.9, 2.8, 3.6, and 2.4, respectively), while\u0026nbsp;age\u0026nbsp;≥ 75 years was not a significant adverse prognostic factor (Table 2).\u0026nbsp;Similarly, a preoperative CONUT score\u0026nbsp;≥\u0026nbsp;4, CA19-9\u0026nbsp;≥\u0026nbsp;95.7\u0026nbsp;U/mL,\u0026nbsp;poorly-differentiated adenocarcinoma or adenosquamous carcinoma,\u0026nbsp;and existence of LNM\u0026nbsp;were poor prognostic factors for\u0026nbsp;DSS (HR: 3.0, 2.8, 2.4, and 2.2, respectively), while\u0026nbsp;age\u0026nbsp;≥ 75 years was not a significant adverse prognostic factor (Supplemental Table 1).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eRecurrence status and risk factors for short RTD\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe patient characteristics at the time of recurrence are shown in Table 3. At the time of recurrence, serum albumin level, LMR, and PNI were significantly lower and the GPS and CONUT score were significantly higher in patients ≥ 75 years (P = 0.035, 0.045, 0.028, 0.049, and 0.028, respectively). Moreover, the treatment rate after recurrence was also significantly lower in older patients (44% in patients ≥ 75 years, 81% in patients \u0026lt; 75 years; P = 0.0091). The median time from RTD in patients aged ≥ 75 years was significantly shorter than that in patients aged \u0026lt; 75 years (0.6 years vs 1.3 years, P = 0.020) (Figure 2). In multivariate analysis, age ≥ 75 years, CONUT score ≥ 4, poorly-differentiated adenocarcinoma or adenosquamous carcinoma, and failure to implement treatment after recurrence were independent risk factors for a short time from RTD (HR: 3.5, 5.3, 4.7, and 5.8, respectively) (Table 4). When assessing outcomes using only age ≥ 75 years and CONUT score ≥ 4, which can be easily assessed preoperatively, recurrent patients with risk scores of 1-2 had a significantly shorter time from RTD than patients with a risk score of zero (median RTD: 0.6 and 1.4 years, P = 0.0016) (Supplemental Figure 1). Furthermore, in multivariate analyses, only age ≥ 75 years (odds ratio: 0.24, P = 0.041) was an independent risk factor for implementation of treatment after recurrence (Table 5).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis study revealed no significant differences in postoperative mortality and morbidity, RFS, DSS, and OS between patients aged\u0026thinsp;\u0026ge;\u0026thinsp;75 years and those aged\u0026thinsp;\u0026lt;\u0026thinsp;75 years who underwent PD. In contrast, at the time of recurrence, immuno-inflammatory indexes and nutritional indicators were significantly worse in patients aged\u0026thinsp;\u0026ge;\u0026thinsp;75 years and the median survival time from RTD was significantly shorter compared to patients aged\u0026thinsp;\u0026lt;\u0026thinsp;75 years. In addition, age\u0026thinsp;\u0026ge;\u0026thinsp;75 years was an independent risk factor for not receiving treatment after recurrence. These findings suggest that older patients with recurrence may have a poor general condition due to various factors as well as a shorter RTD due to difficulty in implementing treatment after recurrence. These findings may be useful when considering treatment strategies for older patients with DC.\u003c/p\u003e \u003cp\u003eBTC was previously more prevalent in Asia, but its incidence has been increasing worldwide in recent years.\u003csup\u003e\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e BTC is one of the gastrointestinal cancers with a poor prognosis, and the only curative treatment is surgical resection. However, recurrence is often observed even after radical resection\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e and the 5-year survival rate in patients with BTC after curative resection has been reported to be as low as approximately 20%.\u003csup\u003e36\u003c/sup\u003e In Japan, BTC is the sixth leading cause of cancer-related deaths, accounting for approximately 18 000 deaths per year.\u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e The surgical methods for DC, which is a type of BTC, include extrahepatic bile duct resection, PD, and HPD. With regard to the surgery-related complications and prognosis, PD with regional LND is currently the standard surgical procedure for resectable DC.\u003csup\u003e\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e PD is also used for the treatment of pancreatic head and ampullary carcinomas. Therefore, it is important to investigate the safety and efficacy of PD in older patients. Despite the recent advances in medical technology, PD carries a certain degree of morbidity and mortality.\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan additionalcitationids=\"CR18 CR19 CR20 CR21 CR22 CR23\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e As mentioned earlier, there are conflicting reports regarding the safety and effectiveness of PD in older patients as compared to younger patients. Studies that claimed that PD was as safe in older patients as in younger patients were mainly conducted in high-volume centers that provide high-quality medical care.\u003csup\u003e\u003cspan additionalcitationids=\"CR18 CR19\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e Conversely, a real-world large-scale study in Japan revealed that the overall hospital mortality rate after PD was 2.2%, with patients aged 70 years or older having higher postoperative mortality and complication rates, and longer length of postoperative hospital stay than those aged 70 years or younger.\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e Thus, the safety of PD in older patients remains a crucial unresolved issue in these times of expanding life expectancy, as it varies depending on patient background characteristics and study population. In this study, the hospital mortality rate was favorable, and the length of postoperative hospital stay was shorter than that reported in the aforementioned large-scale study, indicating that the results of this study are safer and more reliable.\u003c/p\u003e \u003cp\u003eIn cases of recurrence after radical resection, multidisciplinary treatment is administered, which mainly comprises drug therapy, but the median OS remains low at approximately 1 year.\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e,\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e Although recent studies have demonstrated improvement in prognosis of patients undergoing GCD and GCS therapy compared to conventional treatment regimens such as GC therapy, the prognosis remains poor, with a median survival time of approximately 12.8 and 16.2 months with GCD and GCS therapy, respectively.\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u003c/sup\u003e Most of the previous clinical trials excluded and/or included only a small number of older patients;\u003csup\u003e\u003cspan additionalcitationids=\"CR33 CR34\" citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u003c/sup\u003e therefore, it remains unclear whether the safety and effectiveness of drug therapy is similar between older and younger patients with DC. Previous studies have reported that poor cognitive and physical function and performance status in older patients make it difficult to continue chemotherapy.\u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e,\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e However, the initiation and continuation of chemotherapy should take into account multiple factors in addition to age, and the decision to initiate chemotherapy should be based on the patient\u0026rsquo;s general condition using a numerical index. Immune-inflammatory and nutritional indicators have been reported as predictors of postoperative prognosis and chemotherapy efficacy in some cancers.\u003csup\u003e\u003cspan additionalcitationids=\"CR15\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e These variables can be readily evaluated preoperatively and may be potentially useful for predicting therapeutic treatability after recurrence. To our knowledge, no previous study has examined the efficacy of these indicators in predicting treatment suitability after recurrence in patients with DC. This study examined various indicators and demonstrated that CONUT score is an important patient factor that affects the treatment after recurrence. In recent years, the concept of frailty has been reported as an indicator of the clinical performance status, and a previous study showed that improved prediction of adverse postoperative outcomes in patients with PD by combining frailty with other factors.\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e Although age was identified as a risk factor for a short survival time from RTD and treatment failure after recurrence in this study, age is merely one factor, and there is a need to explore other patient background characteristics, which are currently difficult to quantify. Future studies should aim to elucidate these factors based on various preoperative measurable parameters that influence treatment after recurrence in older patients with DC to aid clinical decision-making regardless of age. In addition, it is necessary to verify whether improving these indicators through pre- and postoperative interventions will lead to extended survival.\u003c/p\u003e \u003cp\u003eThis study has some limitations. First, over the 24-year study period, patients received different diagnostic tests and treatments, including various chemotherapy regimens and pre-, intra-, and postoperative management plans, owing to advances in these techniques over time. Thus, a selection bias cannot be ruled out, especially for surgical indications and procedures. These variations may have skewed the outcomes of patients treated during different periods of the study. Second, the number of cases and recurrence/death events was insufficient compared to the number of items used in the multivariate analysis. Finally, this was a retrospective study performed at a single institution, which may limit the generalizability of the results. However, this study was conducted as a preliminary pilot study to determine the potential of a larger observational study to clarify the validity of surgical resection in older patients with DC. The results of this study are satisfactory in that they lay the groundwork for further research.\u003c/p\u003e \u003cp\u003eIn conclusion, we demonstrated that PD in patients with DC aged\u0026thinsp;\u0026ge;\u0026thinsp;75 years may be tolerated, but the treatment of recurrent disease in these patients is difficult and they have a shorter RTD.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors thank Editage (www.editage.jp) for\u0026nbsp;the English language editing.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDisclosure of interest\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNone of the authors has any financial or personal relationships with other people or organizations that could potentially and inappropriately influence (bias) our work and conclusions.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding statement\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research did not receive any specific funding from any agencies in the public, commercial, or not-for-profit areas.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDisclosure of statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNone of the authors have any financial and personal relationships with other people or organizations that could potentially and inappropriately influence (bias) our work and conclusions.\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eWI, HK, and DI contributed to conception and design. WI, HK, RS, YN, HA, and DI contributed to development of methodology. WI, HK, RS, YN, HA, YH, TN, KT, SM, KT, KS, KS, SF, YK, and DI contributed to development of data acquisition and analysis. WI, HK, and DI contributed to, writing, reviewing, and/or revising of the manuscript. All authors have read, reviewed, and approved the final manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eJemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69\u0026ndash;90. \u003c/li\u003e\n\u003cli\u003ePatel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002; 3: 10.\u003c/li\u003e\n\u003cli\u003eRizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma \u0026ndash; evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018; 15: 95\u0026ndash;111.\u003c/li\u003e\n\u003cli\u003eNagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, Ebata T, Konishi M, Sano K, Shimada K, Shimizu H, Higuchi R, Wakai T, Isayama H, Okusaka T, Tsuyuguchi T, Hirooka Y, Furuse J, Maguchi H, Suzuki K, Yamazaki H, Kijima H, Yanagisawa A, Yoshida M, Yokoyama Y, Mizuno T, Endo I. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. J Hepatobiliary Pancreat Sci. 2021; 28: 26-54.\u003c/li\u003e\n\u003cli\u003eSmith AM, Liaskos C, Verbeke CS. Impact of intrapancreatic or extrapancreatic bile duct involvement on survival following pancreatoduodenectomy for common bile duct cancer. Br J Surg. 2014; 101: 89\u0026ndash;99.\u003c/li\u003e\n\u003cli\u003eVogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u0026uuml;mpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A, Valle JW, Ducreux M; ESMO Guidelines Committee. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34: 127-140.\u003c/li\u003e\n\u003cli\u003eFernandez-del Castillo C, Morales-Oyarvide V, McGrath D, Wargo JA, Ferrone CR, Thayer SP et al. Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery. 2012; 152: S56\u0026ndash;S63.\u003c/li\u003e\n\u003cli\u003eKakeji Y, Takahashi A, Hasegawa H, Ueno H, Eguchi S, Endo I, Sasaki A, Takiguchi S, Takeuchi H, Hashimoto M, Horiguchi A, Masaki T, Marubashi S, Yoshida K, Gotoh M, Konno H, Yamamoto H, Miyata H, Seto Y, Kitagawa Y, National Clinical Database. Surgical outcomes in gastroenterological surgery in Japan: Report of the National Clinical Database 2011-2018. Ann Gastroenterol Surg 2020; 4: 250\u0026ndash;274.\u003c/li\u003e\n\u003cli\u003eRudnicka E, Napoerala P, Podfigurna A, Meczekalski B, Smolarczyk R, Grymowicz M. The World Health Organization (WHO) approach to healthy ageing. Maturitas. 2020; 139: 6-11.\u003c/li\u003e\n\u003cli\u003eMinistry of Health, Labour and Welfare. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.mhlw.go.jp/toukei/saikin/hw/life/tdfk20/dl/tdfk20-10.pdf\u003c/li\u003e\n\u003cli\u003ehttps://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/koukikourei/index.html\u003c/li\u003e\n\u003cli\u003eLexell J, Taylor CC, Sj\u0026ouml;str\u0026ouml;m M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men J Neurol Sci. 1988; 84: 275-94.\u003c/li\u003e\n\u003cli\u003eStrechler BL：Origin and comparison of the feects of time and high-energy radiations on living systems. Quart Rev Biol. 1959; 34: 117-142.\u003c/li\u003e\n\u003cli\u003eOkuno M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma. J Gastroenterol. 2016; 51: 153\u0026ndash;161.\u003c/li\u003e\n\u003cli\u003eTakagi K, Yagi T, Umeda Y, Shinoura S, Yoshida R, Nobuoka D, Kuise T, Araki H, Fujiwara T. Preoperative controlling nutritional status (CONUT) score for assessment of prognosis following hepatectomy for hepatocellular carcinoma. World J Surg. 2017; 41: 2353\u0026ndash;2360.\u003c/li\u003e\n\u003cli\u003eShiihara M, Higuchi R, Izumo W, Yazawa T, Uemura S, Furukawa T, Yamamoto M. Impact of the controlling nutritional status score on severe postoperative complications of pancreaticoduodenectomy for pancreatic cancer. Langenbecks Arch Surg. 2021; 406: 1491-1498.\u003c/li\u003e\n\u003cli\u003eIzumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Matsunaga Y, Shiihara M, Yamamoto M. Evaluation of the validity of pancreatectomy for very elderly patients with pancreatic ductal adenocarcinoma. Langenbecks Arch Surg. 2021; 406: 1081-1092.\u003c/li\u003e\n\u003cli\u003eSugimachi K, Iguchi T, Mano Y, Nishijima T, Nakanoko T, Uehara H, et al. The impact of immunonutritional and physical status on surgical outcome after pancreaticoduodenectomy in elderly patients. Anticancer Res. 2019; 39: 6347\u0026ndash;53.\u003c/li\u003e\n\u003cli\u003eOkabayashi T, Sui K, Murokawa T, Kimura J, Iwata J, Morita S, et al. Indications for pancreaticoduodenectomy affected postoperative outcomes in octogenarians. Ann Gastroenterol Surg. 2021; 5: 102\u0026ndash;10.\u003c/li\u003e\n\u003cli\u003eIkenaga N, Nakata K, Abe T, Ideno N, Fujimori N, Oono T, et al. Risks and benefits of pancreaticoduodenectomy in patients aged 80 years and over. Langenbecks Arch Surg. 2023; 408: 108.\u003c/li\u003e\n\u003cli\u003eMori Y, Okawara M, Shibao K, Kohi S, Tamura T, Sato N, Fujino Y, Fushimi K, Matsuda S, Hirata K. Short-term outcomes of pancreatoduodenectomy in older individuals over a 9-year period using real-world data: A multilevel analysis based on a nationwide administrative database in Japan. J Hepatobiliary Pancreat Sci. 2024; 31: 262-272.\u003c/li\u003e\n\u003cli\u003eZhang W, Huang Z, Zhang J, Che X. Safety and effectiveness of open pancreaticoduodenectomy in adults aged 70 or older: a meta-analysis. J Geriatr Oncol. 2021; 12: 1136\u0026ndash;45.\u003c/li\u003e\n\u003cli\u003eShaib WL, Zakka K, Hoodbhoy FN, Belalcazar A, Kim S, Cardona K, et al. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. J Geriatr Oncol. 2020; 11: 660\u0026ndash;7.\u003c/li\u003e\n\u003cli\u003eYuan F, Essaji Y, Belley-Cote EP, Gafni A, Latchupatula L, Ruo L, et al. Postoperative complications in elderly patients following pancreaticoduodenectomy lead to increased postoperative mortality and costs. A retrospective cohort study. Int J Surg. 2018; 60: 204\u0026ndash;9\u003c/li\u003e\n\u003cli\u003eCancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare). https://ganjoho.jp/reg_stat/statistics/data/dl/excel/cancer_incidenceNCR(2016-2020).xls\u003c/li\u003e\n\u003cli\u003eHurwitz, E.E.; Simon, M.; Vinta, S.R.; Zehm, C.F.; Shabot, S.M.; Minhajuddin, A.; Abouleish, A.E. Adding Examples to the ASA-Physical Status Classification Improves Correct Assignment to Patients. Anesthesiology 2017, 126, 614\u0026ndash;622\u003c/li\u003e\n\u003cli\u003eAmin MB, American Joint Committee on Cancer. AJCC cancer staging manual. 8th edn. New York, NY: Springer; 2017. \u003c/li\u003e\n\u003cli\u003eDindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240: 205-213.\u003c/li\u003e\n\u003cli\u003eBassi C, Dervenis C, Butturini G, et al, and the International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005; 138: 8-13. \u003c/li\u003e\n\u003cli\u003eWente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007; 142: 761-768. \u003c/li\u003e\n\u003cli\u003eWente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007; 142: 20-25.\u003c/li\u003e\n\u003cli\u003eBridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans TR, Stocken D, Stubbs C, Praseedom R, Ma YT, Davidson B, Neoptolemos J, Iveson T, Cunningham D, Garden OJ, Valle JW, Primrose J; BILCAP study group. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol. 2022; 40: 2048-2057.\u003c/li\u003e\n\u003cli\u003eNakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023; 401: 195-203.\u003c/li\u003e\n\u003cli\u003eIoka T, Kanai M, Kobayashi S, Sakai D, Eguchi H, Baba H, Seo S, Taketomi A, Takayama T, Yamaue H, Takahashi M, Sho M, Kamei K, Fujimoto J, Toyoda M, Shimizu J, Goto T, Shindo Y, Yoshimura K, Hatano E, Nagano H; Kansai Hepatobiliary Oncology Group (KHBO). Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci. 2023; 30: 102-110.\u003c/li\u003e\n\u003cli\u003eOh D, Ruth HA, Qin S, Chen LT, Okusaka T, Vogel A, et al: Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence. 2022; 1: EVIDoa2200015.\u003c/li\u003e\n\u003cli\u003eTawarungruang C, Khuntikeo N, Chamadol N, Laopaiboon V, Thuanman J, Thinkhamrop K, et al. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification. BMC Cancer. 2021; 21: 497.\u003c/li\u003e\n\u003cli\u003echromeextension://efaidnbmnnnibpcajpcglclefindmkaj/https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2024_fig_J.pdf\u003c/li\u003e\n\u003cli\u003eAparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, et al (2013) Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase iii study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 31:1464\u0026ndash;1470\u003c/li\u003e\n\u003cli\u003eExtermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ III, Balducci L (2012) Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 118:3377\u0026ndash;3386\u003c/li\u003e\n\u003cli\u003eAl Abbas AI, Borrebach JD, Pitt HA, Bellon J, Hogg ME, Zeh HJ, 3rd, Zureikat AH. Development of a Novel Pancreatoduodenectomy-Specific Risk Calculator: an Analysis of 10,000 Patients. J Gastrointest Surg. 2021; 25: 1503-1511.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTable 1. Preoperative clinicopathological characteristics of the resected patients with distal cholangiocarcinom\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"1106\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"53.84615384615385%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAge\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eP value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"50.7563025210084%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e\u0026ge; 75 (n=32)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"49.2436974789916%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e\u0026lt;\u0026nbsp;75 (n=68)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAge (years, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e78 (75-86)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e66 (31-74)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003eSex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e21 (66%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e52 (76%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.26\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative BMI (kg/m\u003csup\u003e2\u003c/sup\u003e, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e21.4 (16.0-29.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e21.5 (14.7-41.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.87\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative TP (g/dL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e6.9 (5.5-8.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e6.9 (5.4-8.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.68\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative Alb (g/dL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e3.9 (2.1-4.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e3.8 (2.7-4.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.94\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative TC (mg/dL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e172 (93-256)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e166 (80-378)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.34\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative TG (mg/dL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e104 (51-178)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e108 (43-305)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.80\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative CRP (mg/dL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e0.18 (0.1-2.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e0.23 (0.1-13.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.092\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative HbA1c (%, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e5.6 (4.5-7.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e5.7 (4.4-12.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.15\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative NLR (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e2.2 (1.1-21.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e2.5 (0.78-11.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.66\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative PLR (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e154.0 (64.5-1014.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e166.7 (66.8-511.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.80\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative LMR (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e4.3 (0.89-7.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e4.0 (2.5-10.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.27\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative PNI (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e44.9 (22.1-58.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e44.8 (33.1-64.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.93\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative CAR (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e0.045 (0.022-1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e0.059 (0.020-3.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.15\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative GPS score\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003e0 / 1 / 2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e23 (71%) / 5 (16%) / 4 (13%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e41 (60%) / 19 (25%) / 10 (15%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.49\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative CONUT score\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 4 / \u0026ge; 4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e22 (69%) / 10 (31%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e46 (67%) / 22 (33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.91\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative CEA (ng/mL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e2.3 (0.8-18.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e2.2 (0.8-45.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.77\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative CA19-9 (U/mL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e27.8 (0.6-321)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e31.8 (0.6-44000)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.26\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003eASA-PS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003eClass 1 / 2 / 3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e1 (3%) / 19 (59%) / 12 (38%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e2 (3%) / 47 (69%) / 19 (28%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.62\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003eVascular resection\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003eWith\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e2 (6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e3 (4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.70\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eNumber of dissected lymph node (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e8 (2-43)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e11 (0-36)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.79\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eOperative time (min, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e447 (256-720)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e481 (293-724)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.17\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eBlood loss (ml, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e532 (133-2312)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e673 (247-2831)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.51\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003ePathological type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003ewel / mod / por / ase\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e11 (34%) / 14 (44%) / 5 (16%) / 2 (6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e34 (50%) / 22 (32%) / 11 (16%) 1 (1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.32\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003eStage\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003eⅠ / ⅡA / ⅡB / ⅢA / ⅢB\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e4 (13%) / 13 (40%) / 11 (34%) / 4 (13%) / 0 (0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e7 (10%) / 25 (37%) / 28 (41%) / 7 (10%) / 1 (2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.86\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003eResidual tumor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003eR0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e27 (84%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e46 (68%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.069\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003ePostoperative complication grade\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; Ⅲ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e12 (38%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e21 (31%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.55\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003ePOPF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003eB or C\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e10 (33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e18 (26%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.62\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003eDGE\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003eB or C\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e3 (9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e8 (12%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.72\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003ePPH\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003eB or C\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e1 (3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e0 (0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.13\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.678119349005424%\" valign=\"top\"\u003e\n \u003cp\u003eAdjuvant chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.556962025316455%\" valign=\"top\"\u003e\n \u003cp\u003eWith\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e5 (16%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.491862567811935%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e12 (17%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.967450271247739%\" valign=\"top\"\u003e\n \u003cp\u003e0.80\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePostoperative hospital stay (day, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e28 (9-71)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e27 (9-76)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.84\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eRecurrence\u003c/p\u003e\n \u003cp\u003eLiver\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eLymph node\u003c/p\u003e\n \u003cp\u003eLocal recurrence\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eLung\u003c/p\u003e\n \u003cp\u003eDissemination\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e16 (50%)\u003c/p\u003e\n \u003cp\u003e9 (56%)\u003c/p\u003e\n \u003cp\u003e6 (38%)\u003c/p\u003e\n \u003cp\u003e4 (25%)\u003c/p\u003e\n \u003cp\u003e1 (6%)\u003c/p\u003e\n \u003cp\u003e3 (19%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e36 (53%)\u003c/p\u003e\n \u003cp\u003e11 (31%)\u003c/p\u003e\n \u003cp\u003e11 (31%)\u003c/p\u003e\n \u003cp\u003e9 (25%)\u003c/p\u003e\n \u003cp\u003e7 (19%)\u003c/p\u003e\n \u003cp\u003e4 (11%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.78\u003c/p\u003e\n \u003cp\u003e0.081\u003c/p\u003e\n \u003cp\u003e0.62\u003c/p\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003cp\u003e0.19\u003c/p\u003e\n \u003cp\u003e0.47\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eDead from distal cholangiocarcinoma\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e12 (38%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e26 (38%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.94\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eDead from another disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e5 (16%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e8 (12%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.60\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePostoperative observation period (year, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e2.2 (0.2-14.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e3.5 (0.28-20.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003e0.10\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.18099547511312%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eIn hospital mortality\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 31.0236%;\"\u003e\n \u003cp\u003e0 (0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.5158371040724%\" valign=\"top\" style=\"width: 25.0634%;\"\u003e\n \u003cp\u003e0 (0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.972850678733032%\" valign=\"top\"\u003e\n \u003cp\u003eN.A\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAbbreviations: BMI: body mass index, TP: total protein, Alb: albumin, TC: total cholesterol, TG: triglyceride, CRP: C-reactive protein, HbA1c: hemoglobin A1c, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, LMR: Lymphocyte/Monocyte ratio, PNI: prognostic nutrition index, CAR: C-reactive protein-albumin ratio, GPS: glasgow prognostic score, CONUT: controlling nutritional status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, ASA-PS: American society of anesthesiologists-physical status, PD: pancreaticoduodenectomy, EHBD: extrahepatic bile duct resection, wel: well differentiated adenocarcinoma, mod: moderately differentiated adenocarcinoma, por: poorly differentiated adenocarcinoma, asc: adenosquamous carcinoma, POPF: postoperative pancreatic fistula grade, DGE: delayed gastric empty grade, PPH: post-pancreatectomy hemorrhage, N.A: not avaivalbe\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 2. Univariate and multivariate analyses of prognostic\u0026nbsp;factors for overall survival in resected patients with distal cholangiocarcinoma\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" align=\"\" width=\"737\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.222523744911804%\" colspan=\"3\" valign=\"top\" style=\"width: 27.5793%;\"\u003e\n \u003cp\u003eUnivariate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.64450474898236%\" colspan=\"2\" valign=\"top\" style=\"width: 25.0294%;\"\u003e\n \u003cp\u003eMultivariate\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\"\u003e\n \u003cp\u003ePrognostic factors\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" rowspan=\"2\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eDefinition\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" rowspan=\"2\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003en\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.91044776119403%\" colspan=\"2\" style=\"width: 19.5131%;\"\u003e\n \u003cp\u003eOS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003eP value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003eHazard ratio\u003c/p\u003e\n \u003cp\u003e(95% CI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eP\u0026nbsp;value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"50%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e3-years\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"50%\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e5-years\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAge\u0026nbsp;(years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e68\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e55.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e55.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e67.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e58.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative BMI (kg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 22.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e42\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e71.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e63.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 22.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e58\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e58.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e48.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative TP (g/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 6.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e79\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e67.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e58.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.057\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 6.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e49.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e36.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative Alb (g/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 3.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e71.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e59.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.011\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.72\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 3.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e38.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e38.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.3 (0.29-5.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative TC (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 198\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e83.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e75.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.014\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.21\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 198\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e64\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e52.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e40.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.6 (0.75-3.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative TG (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 104\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e73.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e66.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.0077\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.90\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 104\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e51.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e37.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.1 (0.51-2.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative CRP (mg/dl)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e54\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e74.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e66.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.018\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.77\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e50.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e40.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.3 (0.23-7.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative HbA1c (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 7.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e88\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e64.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e55.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.79\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 7.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e56.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e42.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative NLR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 2.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e65.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e62.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.094\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 2.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e62.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e46.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative PLR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 131.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e73.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e73.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.025\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.95\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 131.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e58.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e45.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.1 (0.41-2.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative LMR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 2.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e80\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e67.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e60.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.0071\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.16\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 2.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e35.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e2.0 (0.76-5.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative PNI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 40.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e78\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e72.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e63.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.47\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 40.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e34.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e22.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.6 (0.46-5.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative CAR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 0.054\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e86\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e75.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e65.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.028\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.97\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 0.054\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e52.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e43.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.1 (0.21-5.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative GPS score\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e0-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e86\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e67.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e55.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.041\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.62\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e42.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e42.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.5 (0.32-6.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative CONUT score\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e0-3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e68\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e74.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e66.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.0064\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e41.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e29.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e4.9 (1.5-15.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative CEA (ng/mL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 10.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e96\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e64.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e54.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.80\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 10.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePreoperative CA19-9 (U/mL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026lt; 95.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e67.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e56.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.082\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge; 95.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e78\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e51.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e45.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eASA-PS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eClass 1-2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e69\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e69.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e63.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.0045\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.88\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eClass 3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e50.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e29.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.1 (0.52-2.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eVascular resection\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eWithout\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e95\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e66.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e55.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.029\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.17\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eWith\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e20.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e20.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e2.5 (0.68-9.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePostoperative complication\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026le;\u0026nbsp;Ⅱ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e66.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e53.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003e\u0026ge;\u0026nbsp;Ⅲ\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e57.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e53.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePOPF\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eNone or\u0026nbsp;BL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e72\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e66.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e54.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eB or C\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e57.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e52.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eDGE\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eNone or A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e89\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e65.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e54.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eB or C\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePathological type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003ewel + mod\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e81\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e73.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e62.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.011\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003epor + asc\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e26.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e21.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e2.8 (1.3-6.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eT factor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eT 1-2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e73\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e71.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e58.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.0069\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.20\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eT 3-4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e44.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e40.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.7 (0.76-3.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eLymph node metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eNegative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e70.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e63.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.0071\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.023\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003ePositive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e55.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e42.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e3.6 (1.2-11.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eResidual tumor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eR0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e73\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e69.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e59.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.0084\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.017\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.93368700265252%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eR1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.079575596816976%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e49.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.50663129973475%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e41.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.97347480106101%\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e2.4 (1.2-4.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.222523744911804%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAdjuvant chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"12.754409769335142%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eWith\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.156037991858887%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e63.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.955223880597014%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e47.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\" style=\"width: 9.0285%;\"\u003e\n \u003cp\u003e0.66\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.332428765264586%\" rowspan=\"2\" valign=\"top\" style=\"width: 18.0729%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.312075983717774%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"35.60606060606061%\" valign=\"top\" style=\"width: 13.3809%;\"\u003e\n \u003cp\u003eWithout\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.393939393939394%\" valign=\"top\" style=\"width: 9.1282%;\"\u003e\n \u003cp\u003e83\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 8.8066%;\"\u003e\n \u003cp\u003e63.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\" style=\"width: 11.2523%;\"\u003e\n \u003cp\u003e54.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAbbreviations: OS: overall survival rate, CI: confidence interval, BMI: body mass index, TP: total protein, Alb: albumin, TC: total cholesterol, TG: triglyceride, CRP: C-reactive protein, HbA1c: hemoglobin A1c, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, LMR: Lymphocyte/Monocyte ratio, PNI: prognostic nutrition index, CAR: C-reactive protein-albumin ratio, GPS: glasgow prognostic score, CONUT: controlling nutritional status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, ASA-PS: American society of anesthesiologists-physical status, wel: well differentiated adenocarcinoma, mod: moderately differentiated adenocarcinoma, por: poorly differentiated adenocarcinoma, asc: adenosquamous carcinoma, POPF: postoperative pancreatic fistula grade, BL: biochemical leak, DGE: delayed gastric empty grade\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 3. Clinicopathological characteristics of the recurrent patients at the time of recurrence\u0026nbsp;\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"1106\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"51.265822784810126%\" colspan=\"2\" valign=\"top\" style=\"width: 45.0476%;\"\u003e\n \u003cp\u003eAge\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" rowspan=\"2\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003eP value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"53.26278659611993%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e\u0026ge; 75 (n=16)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"46.73721340388007%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e\u0026lt;\u0026nbsp;75 (n=36)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAge at the time of first surgery\u0026nbsp;(years, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e78 (75-86)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e69 (31-74)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\"\u003e\n \u003cp\u003eSex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.665158371040723%\" valign=\"top\"\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e8 (50%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.981900452488688%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e30 (83%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.015\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTP at the time of recurrence (g/dL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e6.7 (6.0-7.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e6.8 (5.8-7.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.66\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAlb at the time of recurrence (g/dL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e3.5 (2.4-4.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e3.8 (2.1-4.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.035\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTC at the time of recurrence (mg/dL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e140 (66-238)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e147 (99-266)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.83\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTG at the time of recurrence (mg/dL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e90 (45-158)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e91 (41-277)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.64\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCRP at the time of recurrence (mg/dL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e0.43 (0.1-9.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e0.14 (0.1-18.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.92\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eNLR at the time of recurrence (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e2.7 (0.76-8.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e2.2 (0.68-17.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.56\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePLR at the time of recurrence (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e170.2 (71.3-368.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e165.5 (22.4-377.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.27\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eLMR at the time of recurrence (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e2.8 (0.82-5.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e4.1 (1.0-9.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.045\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePNI at the time of recurrence (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e39.0 (28.4-51.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e44.9 (29.6-53.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.028\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCAR at the time of recurrence (range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e0.14 (0.024-4.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e0.041 (0.023-7.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.92\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\"\u003e\n \u003cp\u003eGPS score at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.665158371040723%\" valign=\"top\"\u003e\n \u003cp\u003e0-1 / 2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e6 (37%) / 10 (63%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.981900452488688%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e24 (67%) / 12 (33%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.049\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\"\u003e\n \u003cp\u003eCONUT score at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.665158371040723%\" valign=\"top\"\u003e\n \u003cp\u003e0-4 / \u0026ge; 5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e8 (50%) / 8 (50%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.981900452488688%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e29 (81%) / 7 (19%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.028\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCEA at the time of recurrence (ng/mL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e4.0 (1.4-41.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e3.9 (0.7-17.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.14\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCA19-9 at the time of recurrence (U/mL, range)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e113.5 (5.1-1856)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e51.7 (5.5-1162)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.11\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\"\u003e\n \u003cp\u003ePathological type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.665158371040723%\" valign=\"top\"\u003e\n \u003cp\u003ewel or mod / por or asc\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e11 (69%) / 5 (31%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.981900452488688%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e27 (75%) / 9 (25%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.64\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\"\u003e\n \u003cp\u003eTreatment after recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.665158371040723%\" valign=\"top\"\u003e\n \u003cp\u003eWith\u003c/p\u003e\n \u003cp\u003eChemotherapy\u003c/p\u003e\n \u003cp\u003eRadiation\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;Surgical resection\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.330316742081447%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e7 (44%)\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;8 (100%)\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;0 (0%)\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;0 (0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.981900452488688%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e29 (81%)\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;27 (92%)\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; 1 (4%)\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; 1 (4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.6923076923076925%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.0091\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eDead from distal cholangiocarcinoma\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e11 (69%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e23 (64%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.73\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.04882459312839%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eDead from another disease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.305605786618443%\" valign=\"top\" style=\"width: 24.5901%;\"\u003e\n \u003cp\u003e0 (0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.960216998191683%\" valign=\"top\" style=\"width: 21.1345%;\"\u003e\n \u003cp\u003e2 (12%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.685352622061483%\" valign=\"top\" style=\"width: 14.2278%;\"\u003e\n \u003cp\u003e0.60\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAbbreviations: TP: total protein, Alb: albumin, TC: total cholesterol, TG: triglyceride, CRP: C-reactive protein, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, LMR: Lymphocyte/Monocyte ratio, PNI: prognostic nutrition index, CAR: C-reactive protein-albumin ratio, GPS: glasgow prognostic score, CONUT: controlling nutritional status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, wel: well differentiated adenocarcinoma, mod: moderately differentiated adenocarcinoma, por: poorly differentiated adenocarcinoma, asc: adenosquamous carcinoma\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 4. Univariate and multivariate analyses of\u0026nbsp;risk factors for short time from recurrence to death in recurrent patients with distal cholangiocarcinoma\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" align=\"\" width=\"775\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.58139534883721%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.05426356589147%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.072351421188631%\" valign=\"top\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.036175710594314%\" colspan=\"2\" valign=\"top\" style=\"width: 25.034%;\"\u003e\n \u003cp\u003eUnivariate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.25581395348837%\" colspan=\"2\" valign=\"top\" style=\"width: 31.7776%;\"\u003e\n \u003cp\u003eMultivariate\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\"\u003e\n \u003cp\u003ePrognostic factors\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003eDefinition\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003en\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003eMedian RTD (years)\u003c/p\u003e\n \u003cp\u003e(95% CI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003eP value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003eHazard ratio\u003c/p\u003e\n \u003cp\u003e(95% CI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" valign=\"top\"\u003e\n \u003cp\u003eP\u0026nbsp;value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAge\u0026nbsp;at the time of first surgery\u0026nbsp;(years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.3 (0.74-1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.020\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.022\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.52 (0.17-1.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e3.5 (1.2-9.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTP at the time of recurrence (g/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 6.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.0 (0.73-2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.081\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" rowspan=\"2\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 6.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.242424242424242%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"45.75757575757576%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.73 (0.17-1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAlb at the time of recurrence (g/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 3.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.0 (0.74-1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.048\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.52\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 3.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.64 (0.20-1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.7 (0.35-8.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTC at the time of recurrence (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 198\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.4 (0.44-2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" rowspan=\"2\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 198\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.242424242424242%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"45.75757575757576%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.99 (0.64-1.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTG at the time of recurrence (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 104\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.0 (0.64-2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.82\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" rowspan=\"2\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 104\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.242424242424242%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"45.75757575757576%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.0 (0.51-1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCRP at the time of recurrence (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.3 (0.68-2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.074\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" rowspan=\"2\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.242424242424242%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"45.75757575757576%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.77 (0.51-1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eNLR at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 2.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.3 (1.0-2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.031\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.14\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 2.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.68 (0.44-0.99)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.8 (0.82-4.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePLR at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 131.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e4.3 (0.51-NA)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.026\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.24\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 131.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e35\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.77 (0.61-1.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.8 (0.82-4.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eLMR at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 2.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.3 (0.73-2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.028\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.45\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 2.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.64 (0.14-0.99)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.5 (0.5-4.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePNI at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 40.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.4 (0.74-2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.0029\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.93\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 40.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.61 (0.24-0.99)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.1 (0.16-7.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCAR at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 0.054\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.4 (0.73-3.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.017\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.35\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 0.054\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.74 (0.51-1.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.7 (0.55-5.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eGPS score at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e0-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.0 (0.73-1.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.039\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.84\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.55 (0.072-2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.1 (0.30-4.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCONUT score at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e0-3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.4 (0.99-2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.0053\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.030\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.61 (0.32-1.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e5.3 (1.2-23.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCEA at the time of recurrence (ng/mL)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 10.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.0 (0.68-1.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.011\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.43\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 10.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.5 (0.14-0.73)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.8 (0.40-8.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCA19-9 at the time of recurrence (U/mL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026lt; 95.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.4 (0.64-2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.030\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.96\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003e\u0026ge; 95.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.88 (0.44-1.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0 (0.40-2.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePathological type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003ewel + mod\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.57 (0.24-1.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.019\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003epor + asc\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.3 (0.74-2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e4.7 (2.0-11.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eT factor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003eT 1-2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.3 (0.73-1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" rowspan=\"2\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003eT 3-4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.242424242424242%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"45.75757575757576%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.69 (0.26-1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eLymph node metastasis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003eNegative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.3 (0.51-1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.84\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" rowspan=\"2\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003ePositive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.242424242424242%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"45.75757575757576%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.0 (0.61-1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eResidual tumor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003eR0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.0 (0.64-2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" rowspan=\"2\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003eR1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.242424242424242%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"45.75757575757576%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.0 (0.51-1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAdjuvant chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003eWith\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.4 (0.73-2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e0.19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" rowspan=\"2\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003eWithout\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.242424242424242%\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"45.75757575757576%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.99 (0.53-1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"25.614489003880983%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eImplementation of treatment after recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.076326002587322%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003eImplemented\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.0802069857697285%\" valign=\"top\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.534282018111256%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e1.3 (1.0-2.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\" style=\"width: 8.5122%;\"\u003e\n \u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.618369987063389%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.538163001293661%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"29.79683972911964%\" valign=\"top\" style=\"width: 10.3918%;\"\u003e\n \u003cp\u003eNot implemented\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.609480812641083%\" valign=\"top\" style=\"width: 7.9846%;\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"34.08577878103837%\" valign=\"top\" style=\"width: 18.5598%;\"\u003e\n \u003cp\u003e0.41 (0.14-0.64)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.507900677200904%\" valign=\"top\" style=\"width: 24.8211%;\"\u003e\n \u003cp\u003e5.8 (2.1-15.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAbbreviations: RTD: time from recurrence to death, CI: confidence interval, TP: total protein, Alb: albumin, TC: total cholesterol, TG: triglyceride, CRP: C-reactive protein, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, LMR: Lymphocyte/Monocyte ratio, PNI: prognostic nutrition index, CAR: C-reactive protein-albumin ratio, GPS: glasgow prognostic score, CONUT: controlling nutritional status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, wel: well differentiated adenocarcinoma, mod: moderately differentiated adenocarcinoma, por: poorly differentiated adenocarcinoma, asc: adenosquamous carcinoma\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cp\u003eTable 5. Univariate and multivariate analyses of\u0026nbsp;risk factors for implementation of treatment after recurrence in patients with disease recurrence\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" align=\"\" width=\"784\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.076433121019107%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eUnivariate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.076433121019107%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eMultivariate\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\"\u003e\n \u003cp\u003ePrognostic factors\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\"\u003e\n \u003cp\u003eDefinition\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003en\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003eImplement of treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\"\u003e\n \u003cp\u003eOR (95% CI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" valign=\"top\"\u003e\n \u003cp\u003eP value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003eOR (95% CI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" valign=\"top\"\u003e\n \u003cp\u003eP\u0026nbsp;value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAge\u0026nbsp;at the time of first surgery (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e29 (81%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.011\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.041\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"17.276422764227643%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 75\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.585365853658537%\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.13821138211382%\" valign=\"top\"\u003e\n \u003cp\u003e7 (44%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\"\u003e\n \u003cp\u003e0.19 (0.052-0.68)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\"\u003e\n \u003cp\u003e0.24 (0.062-0.94)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTP at the time of recurrence (g/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 6.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e29 (79%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.077\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 6.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e8 (53%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e0.32 (0.088-1.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAlb at the time of recurrence (g/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 3.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e26 (79%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 3.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e11 (58%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e0.37 (0.11-1.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTC at the time of recurrence (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 198\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e7 (100%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eN.A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 198\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e30 (67%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003eN.A\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eTG at the time of recurrence (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 104\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e16 (84%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 104\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e21 (64%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e0.33 (0.079-1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCRP at the time of recurrence (mg/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e21 (78%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e16 (64%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e0.51 (0.15-1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eNLR at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 2.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e23 (82%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.065\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 2.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e14 (58%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e0.30 (0.086-1.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePLR at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 131.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e14 (82%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 131.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e23 (66%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e0.41 (0.098-1.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eLMR at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 2.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e27 (75%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 2.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e10 (63%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e0.56 (0.16-2.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003ePNI at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 40.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e27 (82%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.030\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.24\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"17.276422764227643%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 40.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.585365853658537%\"\u003e\n \u003cp\u003e19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.13821138211382%\" valign=\"top\"\u003e\n \u003cp\u003e10 (53%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\"\u003e\n \u003cp\u003e0.25(0.070-0.87)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\"\u003e\n \u003cp\u003e0.24 (0.022-2.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCAR at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 0.054\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e20 (80%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 0.054\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e17 (63%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e0.43 (0.12-1.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eGPS score at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e0-1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e32 (73%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.56\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e5 (63%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e0.63 (0.13-3.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCONUT score at the time of recurrence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e0-3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e25 (83%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.028\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.94\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"17.276422764227643%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.585365853658537%\"\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"21.13821138211382%\" valign=\"top\"\u003e\n \u003cp\u003e12 (55%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\"\u003e\n \u003cp\u003e0.24 (0.067-0.86)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25%\" valign=\"top\"\u003e\n \u003cp\u003e0.92 (0.084-10.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCEA at the time of recurrence (ng/mL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 10.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e37 (77%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eN.A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 10.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e0 (0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003eN.A\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCA19-9 at the time of recurrence (U/mL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026lt; 95.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\"\u003e\n \u003cp\u003e31\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e22 (71%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026ge; 95.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\"\u003e\n \u003cp\u003e21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e15 (71%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e1.0 (0.30-3.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"20.50955414012739%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eAdjuvant chemotherapy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.828025477707007%\" valign=\"top\"\u003e\n \u003cp\u003eWith\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.261146496815287%\" valign=\"top\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.248407643312103%\" valign=\"top\"\u003e\n \u003cp\u003e11 (92%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" valign=\"top\"\u003e\n \u003cp\u003e1.0\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e0.10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.668789808917197%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.40764331210191%\" rowspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"23.035230352303522%\" valign=\"top\"\u003e\n \u003cp\u003eWithout\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.447154471544716%\" valign=\"top\"\u003e\n \u003cp\u003e43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.18428184281843%\" valign=\"top\"\u003e\n \u003cp\u003e26 (65%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"33.333333333333336%\" valign=\"top\"\u003e\n \u003cp\u003e0.17 (0.020-1.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAbbreviations: OR: odds ratio, CI: confidence interval, TP: total protein, Alb: albumin, TC: total cholesterol, N.A: not available, TG: triglyceride, CRP: C-reactive protein, NLR: neutrophil-lymphocyte ratio, PLR: platelet-lymphocyte ratio, LMR: Lymphocyte/Monocyte ratio, PNI: prognostic nutrition index, CAR: C-reactive protein-albumin ratio, GPS: glasgow prognostic score, CONUT: controlling nutritional status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, wel: well differentiated adenocarcinoma, mod: moderately differentiated adenocarcinoma, por: poorly differentiated adenocarcinoma, asc: adenosquamous carcinoma\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"langenbecks-archives-of-surgery","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"laos","sideBox":"Learn more about [Langenbeck's Archives of Surgery](http://link.springer.com/journal/423)","snPcode":"423","submissionUrl":"https://submission.nature.com/new-submission/423/3","title":"Langenbeck's Archives of Surgery","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"elderly, pancreatoduodenectomy, distal cholangiocarcinoma, prognosis, recurrence","lastPublishedDoi":"10.21203/rs.3.rs-4688865/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4688865/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eThis retrospective study investigated the validity of pancreatoduodenectomy (PD) with regard to recurrence in older patients with distal cholangiocarcinoma (DC).\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eWe compared 32 patients aged\u0026thinsp;\u0026ge;\u0026thinsp;75 years and 68 patients aged\u0026thinsp;\u0026lt;\u0026thinsp;75 years who underwent PD for DC, and evaluated the relationship between age, clinicopathological factors, and outcomes.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003ePostoperative mortality and morbidity rates did not differ between the groups. Although there were no significant differences in 5-year recurrence, disease-specific survival, and overall survival rates between the groups (44.5, 61.5, and 55.0% in patients\u0026thinsp;\u0026ge;\u0026thinsp;75 years and 48.7%, 63.0%, and 58.5% in patients\u0026thinsp;\u0026lt;\u0026thinsp;75 years; P\u0026thinsp;=\u0026thinsp;0.82, 0.57, and 0.34, respectively), the median time from recurrence to death (RTD) in older patients was significantly shorter than that in younger patients (0.6 years vs 1.3 years, P\u0026thinsp;=\u0026thinsp;0.020). In multivariate analysis, age\u0026thinsp;\u0026ge;\u0026thinsp;75 years (hazard ratio [HR]: 3.5), controlling nutritional status (CONUT) score\u0026thinsp;\u0026ge;\u0026thinsp;4 (HR: 4.7), poorly-differentiated adenocarcinoma or adenosquamous carcinoma (HR: 4.7), and failure to implement treatment after recurrence (HR: 5.8) were independent risk factors for a short time from RTD. Furthermore, at the time of recurrence, older patients had significantly poorer serum albumin levels, prognostic nutrition index, Glasgow prognostic score, and CONUT score. Age\u0026thinsp;\u0026ge;\u0026thinsp;75 years (odds ratio: 0.24) was an independent risk factor for implementation of treatment after recurrence.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003ePD in older patients may be acceptable; however, the median time from RTD was shorter owing to lower nutritional status and rates of treatment implementation after recurrence.\u003c/p\u003e","manuscriptTitle":"Evaluation of the validity of pancreatoduodenectomy in older patients with distal cholangiocarcinoma in terms of recurrence","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-08-09 16:53:11","doi":"10.21203/rs.3.rs-4688865/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-02-10T13:53:46+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-01-29T04:49:27+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"115467147342211255717284184988770247280","date":"2025-01-27T01:07:33+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"236811050328266758491616166628961061533","date":"2025-01-26T18:13:22+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-07-24T20:08:55+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"323411604037443389993996567490440554518","date":"2024-07-14T18:38:59+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-07-12T04:53:44+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-07-10T05:05:45+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-07-08T10:32:54+00:00","index":"","fulltext":""},{"type":"submitted","content":"Langenbeck's Archives of Surgery","date":"2024-07-05T01:01:34+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"langenbecks-archives-of-surgery","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"laos","sideBox":"Learn more about [Langenbeck's Archives of Surgery](http://link.springer.com/journal/423)","snPcode":"423","submissionUrl":"https://submission.nature.com/new-submission/423/3","title":"Langenbeck's Archives of Surgery","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"7e618bc1-f844-4a47-b8a8-8f0e66927bae","owner":[],"postedDate":"August 9th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-04-07T16:04:11+00:00","versionOfRecord":{"articleIdentity":"rs-4688865","link":"https://doi.org/10.1007/s00423-025-03694-9","journal":{"identity":"langenbecks-archives-of-surgery","isVorOnly":false,"title":"Langenbeck's Archives of Surgery"},"publishedOn":"2025-04-03 15:57:03","publishedOnDateReadable":"April 3rd, 2025"},"versionCreatedAt":"2024-08-09 16:53:11","video":"","vorDoi":"10.1007/s00423-025-03694-9","vorDoiUrl":"https://doi.org/10.1007/s00423-025-03694-9","workflowStages":[]},"version":"v1","identity":"rs-4688865","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4688865","identity":"rs-4688865","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}